227 results on '"Nucleosides adverse effects"'
Search Results
2. Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000-Korean outcome study.
- Author
-
Lim J, Lee JB, An J, Song GW, Kim KM, Lee HC, and Shim JH
- Subjects
- Antiviral Agents adverse effects, Hepatitis B virus, Humans, Male, Nucleosides adverse effects, Outcome Assessment, Health Care, Republic of Korea, Colorectal Neoplasms chemically induced, Colorectal Neoplasms complications, Colorectal Neoplasms drug therapy, Hepatitis B, Chronic complications
- Abstract
Evidence on the carcinogenicity of oral nucleos(t)ide analogues (NAs) is inconclusive and lacks data on the effects by chemical structure of the NAs in patients with chronic hepatitis B (CHB). We aimed to provide definitive results on this issue using a large set of CHB patients and data on all major NA drugs. The study population consisted of 10,331 patients with CHB receiving primary NA treatment for more than 6 months, and 24,836 untreated controls followed for at least as long as the treated patients. Using the inverse-probability-of-treatment-weighted (IPTW) method, the cumulative incidence of extrahepatic cancers was compared in the treated and untreated patients and across the cyclopentane, L-nucleoside and acyclic phosphonate categories of NAs. Analyses of individual cancers as sub-endpoints were also performed. The cumulative incidence of overall extrahepatic malignancies did not differ between the two groups in the IPTW cohort (hazard ratio [HR] 1.002; 95% confidence interval [CI] [0.859-1.169]). Similar statistical trends were observed in analyses across the three NA chemical subsets and controls. Per-cancer analyses indicated that NA treatment was significantly associated with increased risks of colorectal/anal cancers (HRs [95% CI], 1.538 [1.175-2.013]) and lymphoma (1.784 [1.196-2.662]). Conversely, breast cancer (HRs [95% CI], 0.669 [0.462-0.967]) and prostate cancer (0.521 [0.329-0.825]) were less prevalent in the NA-treated group. In conclusion, prolonged NA treatment presents carcinogenic risks for colorectal/anal and lymphoid tissues in CHB patients, although it does not affect most extrahepatic organs. The protective effect of NAs on breast and prostate cancers should be confirmed., (© 2022 John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
3. Keystone to Secure Safety After Stopping Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B Patients.
- Author
-
Liu YC, Jeng WJ, and Chen CH
- Subjects
- Antiviral Agents adverse effects, DNA, Viral, Hepatitis B Surface Antigens, Hepatitis B e Antigens, Hepatitis B virus genetics, Humans, Nucleosides adverse effects, Treatment Outcome, Hepatitis B, Chronic drug therapy
- Published
- 2022
- Full Text
- View/download PDF
4. Severe Acute Exacerbation After Cessation of Nucleos(t)ide Analog for Chronic Hepatitis B: A Real-World Study of Routine Practice.
- Author
-
Hsu YC, Wu JL, Tseng CH, Nguyen MH, Lin CW, and Hung CL
- Subjects
- Humans, Antiviral Agents adverse effects, DNA, Viral, Hepatitis B e Antigens, Hepatitis B Surface Antigens, Hepatitis B virus genetics, Nucleosides adverse effects, Treatment Outcome, Withholding Treatment, Hepatitis B, Chronic, Disease Progression
- Abstract
There is an ongoing debate as to whether patients with chronic hepatitis B (CHB) may discontinue nucleos(t)ide analogue (NA) therapy before seroclearance of hepatitis B surface antigen (HBsAg).
1 Whereas treatment discontinuation may facilitate HBsAg seroclearance and avoid indefinite drug exposure,2 reactivation of viral replication almost always follows treatment cessation and frequently leads to clinical flares.3 In patients who encounter withdrawal flares, severe acute exacerbation (SAE) could occur with fatal consequences.4 Quantitative knowledge about the risk of SAE is imperative to inform the debate and also the practice., (Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
5. Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy.
- Author
-
Burdette DL, Lazerwith S, Yang J, Chan HLY, Delaney Iv WE, Fletcher SP, Cihlar T, and Feierbach B
- Subjects
- Animals, Antiviral Agents pharmacology, Antiviral Agents therapeutic use, DNA, Viral, Hepatitis B virus genetics, Humans, Mice, Nucleosides adverse effects, Virus Replication, Hepatitis B, Chronic
- Abstract
Nucleos(t)ide analogs are standard-of-care for the treatment of chronic hepatitis B and can effectively reduce hepatitis B virus (HBV) replication but rarely leads to cure. Nucleos(t)ide analogs do not directly eliminate the viral episome, therefore treatment cessation typically leads to rapid viral rebound. While treatment is effective, HBV DNA is still detectable (although not quantifiable) in the periphery of the majority of nucleos(t)ide analog treated HBV patients, even after prolonged treatment. Addressing whether the detectable HBV DNA represents infectious virus is a key unknown and has important implications for the development of a curative treatment for HBV. The minimum HBV genome equivalents required to establish infection in human liver chimeric mice was determined by titration of HBV patient sera and the infectivity in chimeric mice of serum from patients (n = 7) suppressed to the limit of detection on nucleos(t)ide analog therapy was evaluated. A minimum of 5 HBV genome equivalents were required to establish infection in the chimeric mice, confirming this model has sufficient sensitivity to determine whether serum from virally suppressed patients contains infectious virus. Strikingly, serum from 75% (n = 3 out of 4) of nucleos(t)ide-treated HBV patients with DNA that was detectable, but below the lower limit of quantitation, also established infection in the chimeric mice. These results demonstrate that infectious virus is still present in some HBV patients on suppressive nucleos(t)ide therapy. This residual virus may support viral persistence via continuous infection and explain the ongoing risk for HBV-related complications despite long-term suppression on therapy. Thus, additional treatment intensification may facilitate HBV cure., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: D.L.B., S.L., J.Y., W.E.D., and B.F. are current or previous employees of Gilead Sciences (except H.L.Y.C.) and have received a salary and stock ownership as compensation for their employment. The study was funded in full by Gilead Sciences, Inc. HLYC is an advisor of AbbVie, Aligos, Arbutus, Hepions, Gilead Sciences, Janssen, Merck, Glaxo-Smith-Kline, Roche, Vaccitech, VenatoRx, Vir Biotechnology, and a speaker for Gilead Sciences, Mylan and Roche. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2022
- Full Text
- View/download PDF
6. Insufficient immunity led to virologic breakthrough in NAs-treated chronic hepatitis B patients switching to Peg-IFN-ɑ.
- Author
-
Huang D, Yan W, Han M, Yuan W, Wang P, Chen Y, Wan X, Luo X, Wu D, and Ning Q
- Subjects
- Adolescent, Adult, Aged, Antiviral Agents pharmacology, Female, Hepatitis B, Chronic virology, Humans, Immunity drug effects, Interferon-alpha pharmacokinetics, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear virology, Male, Middle Aged, Nucleosides adverse effects, Nucleosides analogs & derivatives, Young Adult, Antiviral Agents therapeutic use, Drug Substitution adverse effects, Hepatitis B virus drug effects, Hepatitis B, Chronic drug therapy, Hepatitis B, Chronic immunology, Interferon-alpha therapeutic use, Nucleosides therapeutic use
- Abstract
Background: Virologic breakthrough (VBT) may occur in chronic hepatitis B (CHB) patients after switching from nucleos(t)ide analogues (NAs) to pegylated interferon alpha (Peg-IFN-ɑ). This study aimed to characterize the clinical and immunological features of VBT., Methods: In NAs-treated patients switching to Peg-IFN-ɑ, innate and adaptive immune cell proportions were examined in peripheral blood and liver biopsy specimens. In vitro effect of IFN-ɑ on the expressions of toll-like receptors 2 (TLR2) and programmed cell death ligand 1 (PDL1) on monocytes, programmed cell death 1 (PD1) on CD8
+ T cells was examined. Peripheral blood mononuclear cells (PBMCs) were treated with TLR2 agonist and/or PDL1 blockade to evaluate their effect on HBV replication., Results: 33 of 166 patients switching to Peg-IFN-ɑ experienced VBT after NA cessation, with majority being hepatitis B e antigen (HBeAg) positive or having higher hepatitis B core-related antigen (HBcrAg) levels. Patients with VBT exhibited lower proportions of TLR2+ monocyte and increased PD1+ HBV-specific CD8+ T cell during the early phase of Peg-IFN-ɑ therapy after NA cessation in peripheral blood, as well as fewer TLR2+ CD68+ macrophages but more PDL1+ CD68+ macrophages and PD1+ CD8+ T cells in liver tissues. Simultaneous use of TLR2 agonist and PDL1 blockage ex vivo suppressed HBV replication by promoting cytokines production and CD8+ T cells cytotoxicity. Upon in vitro IFN-ɑ stimulation, PDL1+ monocytes and PD1+ CD8+ T cells were upregulated, whereas TLR2+ monocytes were not increased in PBMC isolated from HBeAg-positive patients, or those with high HBcrAg titers., Conclusions: In NAs-treated patients, lower TLR2+ monocyte and increased PD1+ HBV-specific CD8+ T cell proportions potentially contribute to VBT after switching to Peg-IFN-ɑ therapy. This insufficient immunity may be associated with the HBeAg status and HBcrAg levels., (Copyright © 2021. Published by Elsevier B.V.)- Published
- 2022
- Full Text
- View/download PDF
7. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
- Author
-
Waters MD, Warren S, Hughes C, Lewis P, and Zhang F
- Subjects
- Amides adverse effects, Amides therapeutic use, Antiviral Agents therapeutic use, Cytidine adverse effects, Cytidine therapeutic use, Deoxyuridine adverse effects, Deoxyuridine analogs & derivatives, Deoxyuridine therapeutic use, Genome, Human drug effects, Humans, Hydroxylamines therapeutic use, Mutagenesis drug effects, Nucleosides therapeutic use, Pyrazines adverse effects, Pyrazines therapeutic use, Ribavirin adverse effects, Ribavirin therapeutic use, SARS-CoV-2 drug effects, Antiviral Agents adverse effects, Cytidine analogs & derivatives, DNA Damage drug effects, Hydroxylamines adverse effects, Nucleosides adverse effects, SARS-CoV-2 genetics, COVID-19 Drug Treatment
- Abstract
This review considers antiviral nucleoside analog drugs, including ribavirin, favipiravir, and molnupiravir, which induce genome error catastrophe in SARS-CoV or SARS-CoV-2 via lethal mutagenesis as a mode of action. In vitro data indicate that molnupiravir may be 100 times more potent as an antiviral agent than ribavirin or favipiravir. Molnupiravir has recently demonstrated efficacy in a phase 3 clinical trial. Because of its anticipated global use, its relative potency, and the reported in vitro "host" cell mutagenicity of its active principle, β-d-N4-hydroxycytidine, we have reviewed the development of molnupiravir and its genotoxicity safety evaluation, as well as the genotoxicity profiles of three congeners, that is, ribavirin, favipiravir, and 5-(2-chloroethyl)-2'-deoxyuridine. We consider the potential genetic risks of molnupiravir on the basis of all available information and focus on the need for additional human genotoxicity data and follow-up in patients treated with molnupiravir and similar drugs. Such human data are especially relevant for antiviral NAs that have the potential of permanently modifying the genomes of treated patients and/or causing human teratogenicity or embryotoxicity. We conclude that the results of preclinical genotoxicity studies and phase 1 human clinical safety, tolerability, and pharmacokinetics are critical components of drug safety assessments and sentinels of unanticipated adverse health effects. We provide our rationale for performing more thorough genotoxicity testing prior to and within phase 1 clinical trials, including human PIG-A and error corrected next generation sequencing (duplex sequencing) studies in DNA and mitochondrial DNA of patients treated with antiviral NAs that induce genome error catastrophe via lethal mutagenesis., (© 2022 Environmental Mutagen Society.)
- Published
- 2022
- Full Text
- View/download PDF
8. Herpes Zoster Following a Nucleoside-Modified Messenger RNA COVID-19 Vaccine.
- Author
-
Dezoteux F, Massip É, Marcant P, Sobaszek A, Chopin MC, Vuotto F, and Staumont-Sallé D
- Subjects
- COVID-19 Vaccines, Humans, Nucleosides adverse effects, RNA, Messenger, SARS-CoV-2, COVID-19, Herpes Zoster diagnosis, Herpes Zoster prevention & control, Herpes Zoster Vaccine adverse effects
- Abstract
Herpes zoster (HZ) was suspected as a predictive cutaneous manifestation of COVID-19, with a debated prognostic significance. We report a series of 5 cases of HZ occurring after vaccination with a nucleoside-modified messenger RNA (mRNA) COVID-19 vaccine (Comirnaty, Pfizer-BioNTech). These new cases do not prove causality between COVID-19 vaccination and HZ. The pathophysiologic mechanism remains elusive, but local vaccine-induced immunomodulation may be involved. The occurrence of HZ does not justify avoiding the second injection of vaccine due to the benefit of vaccination.
- Published
- 2022
- Full Text
- View/download PDF
9. Inappropriate cessation of nucleos(t)ide analog associated with reduced liver transplant-free survival in patients with HBV-related acute on chronic liver failure.
- Author
-
Shi H, Xiao G, Liao M, Zheng L, Jie Y, Lin G, and Chong Y
- Subjects
- Acute-On-Chronic Liver Failure diagnosis, Acute-On-Chronic Liver Failure virology, Adult, Antiviral Agents adverse effects, Disease Progression, Drug Administration Schedule, Female, Hepatitis B diagnosis, Hepatitis B virology, Humans, Male, Middle Aged, Nucleosides adverse effects, Nucleosides analogs & derivatives, Nucleotides adverse effects, Progression-Free Survival, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors, Acute-On-Chronic Liver Failure drug therapy, Antiviral Agents administration & dosage, Hepatitis B drug therapy, Liver Transplantation, Medication Adherence, Nucleosides therapeutic use, Nucleotides therapeutic use
- Abstract
The inappropriate cessation of nucleos(t)ide analog (NA) therapy may lead to acute exacerbations of chronic hepatitis B virus (HBV) infection, acute-on-chronic liver failure (ACLF), and even death. This study aims to elucidate the association between inappropriate NA cessation and prognosis in patients with HBV-ACLF. A total of 901 patients with ACLF were enrolled and stratified into inappropriate NA cessation and non-NA cessation group. Clinical characteristics and prognosis between the two groups were compared. The association between inappropriate NA cessation and the prognosis of patients with HBV-ACLF was evaluated using Cox proportional hazard models after propensity score matching (PSM). NA cessation was identified in 132 patients (NA cessation group), while 769 patients were triggered by other factors (non-NA cessation group). The 28- and 90-day liver transplant-free survival rates were higher in patients with non-NA cessation than in those with NAs cessation (78.3 % vs. 62.1 %, P < 0.001; 62.8 % vs. 44.7 %, P < 0.001). The need for liver transplantation was significantly higher in the NA cessation group compared with the non-NAs cessation group (21.2 % vs. 7.0 %, P < 0.001). The Kaplan-Meier curve showed that inappropriate NA therapy discontinuation had reduced 28- and 90-day live transplant-free survival compared with other precipitating events prior to PSM (all P < 0.001). After matching, the 28- and 90-day transplantation-free survival was also significantly lower in the NA cessation group vs. the non-NA cessation group (P = 0.012 and P = 0.022). In conclusion, the inappropriate cessation of NA therapy is associated with reduced liver transplant-free survival in patients with HBV-related ACLF., (Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
10. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review.
- Author
-
de Fraga RS, Van Vaisberg V, Mendes LCA, Carrilho FJ, and Ono SK
- Subjects
- Antiviral Agents administration & dosage, Humans, Nucleosides administration & dosage, Nucleosides adverse effects, Nucleotides administration & dosage, Nucleotides adverse effects, Antiviral Agents adverse effects, Hepatitis B, Chronic drug therapy
- Abstract
Nucleos(t)ide analogues (NAs) are the main drug category used in chronic hepatitis B (CHB) treatment. Despite the fact that NAs have a favourable safety profile, undesired adverse events (AEs) may occur during the treatment of CHB. Given the eminent number of patients currently receiving NAs, even a small risk of any of these toxicities can represent a major medical issue. The main objective of this review was to analyse information available on AEs associated with the use of NAs in published studies. We choose the following MesH terms for this systematic review: chronic hepatitis B, side effects and treatment. All articles published from 1 January 1990 up to 19 February 2018 in MEDLINE of PubMed, EMBASE, the Cochrane Library and LILACS databases were searched. A total of 120 articles were selected for analysis, comprising 6419 patients treated with lamivudine (LAM), 5947 with entecavir (ETV), 3566 with tenofovir disoproxil fumarate (TDF), 3096 with telbivudine (LdT), 1178 with adefovir dipivoxil (ADV) and 876 with tenofovir alafenamide (TAF). The most common AEs in all NAs assessed were abdominal pain/discomfort, nasopharyngitis/upper respiratory tract infections, fatigue, and headache. TAF displays the highest density of AEs per patient treated among NAs (1.14 AE/treated patient). In conclusion, treatment of CHB with NAs is safe, with a low incidence of AEs. Despite the general understanding TAF being safer than TDF, the number of patients treated with TAF still is too small in comparison to other NAs to consolidate an accurate safety profile. PROSPERO Registration No. CRD42018086471.
- Published
- 2020
- Full Text
- View/download PDF
11. Challenges With Stopping Long-term Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B.
- Author
-
Liem KS, Gehring AJ, Feld JJ, and Janssen HLA
- Subjects
- Antiviral Agents adverse effects, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular prevention & control, Carcinoma, Hepatocellular virology, Consensus, Disease Progression, Drug Administration Schedule, Evidence-Based Medicine standards, Gastroenterology standards, Hepatitis B, Chronic pathology, Hepatitis B, Chronic virology, Humans, Liver Failure pathology, Liver Failure prevention & control, Liver Failure virology, Liver Neoplasms pathology, Liver Neoplasms prevention & control, Liver Neoplasms virology, Nucleosides adverse effects, Nucleosides analogs & derivatives, Practice Guidelines as Topic, Time Factors, Treatment Outcome, Antiviral Agents administration & dosage, Hepatitis B virus isolation & purification, Hepatitis B, Chronic drug therapy, Nucleosides administration & dosage
- Published
- 2020
- Full Text
- View/download PDF
12. Hepatitis B-related glomerulonephritis and optimization of treatment.
- Author
-
Liu Y, Shi C, Fan J, Wang B, and Li G
- Subjects
- Antigen-Antibody Complex immunology, Antiviral Agents therapeutic use, Glomerulonephritis epidemiology, Glomerulonephritis etiology, Hepatitis B, Chronic complications, Hepatitis B, Chronic drug therapy, Humans, Immune Complex Diseases immunology, Immune Complex Diseases pathology, Immune Complex Diseases virology, Immunosuppressive Agents therapeutic use, Interferon-alpha therapeutic use, Kidney immunology, Kidney pathology, Nucleosides adverse effects, Nucleosides therapeutic use, Nucleotides therapeutic use, Glomerulonephritis diagnosis, Glomerulonephritis drug therapy, Hepatitis B, Chronic immunology
- Abstract
Introduction : Multiple studies have revealed a strong relationship between the development of nephropathy and hepatitis B virus (HBV) infection. The underlying pathogenesis of hepatitis B-related glomerulonephritis (HBV-GN) involves immune complexes, which can be isolated from kidney tissues. Clearance of HBV antigenemia improves renal impairment and proteinuria in HBV-GN patients. Areas covered : In this review, we present our current understanding of the epidemiology, pathogenesis, pathology, diagnosis, and treatment of HBV-GN. We discuss the advantages and disadvantages of oral nucleoside/nucleotide analogs (NAs), and the main pharmaceutical treatment for hepatis B. Expert opinion : Currently, antiviral agents are the main HBV-GN therapeutic agents. Although no randomized controlled clinical trials have compared the efficacy of interferon (IFN) and NA, we suggest IFN treatment for pediatric patients (IFN-α in patients ≥1 year; pegIFN-α in patients ≥3 years) considering treatment duration and absence of resistance. Novel NAs have brought about promising treatment options involving high efficacy viral suppression and low resistance rates. NAs with a high barrier to resistance (e.g. entecavir) are recommended as first-line therapy of HBV-GN. Immunosuppression monotherapy, such as corticosteroids, is of little benefit and potentially harmful to HBV-GN patients due to the possibility of viral reactivation.
- Published
- 2020
- Full Text
- View/download PDF
13. [Mechanism relevant to hepatocellular carcinoma occurrence after negative conversion of viral DNA in treatment of chronic hepatitis B patients with nucleos(t)ide drugs].
- Author
-
Gao TJ, Han GY, and Lu FM
- Subjects
- Antiviral Agents adverse effects, China, DNA, Viral, Hepatitis B virus, Hepatitis B, Chronic complications, Humans, Nucleosides adverse effects, Antiviral Agents therapeutic use, Carcinoma, Hepatocellular etiology, Hepatitis B, Chronic drug therapy, Liver Neoplasms etiology, Nucleosides therapeutic use
- Abstract
Hepatocellular carcinoma (HCC) is a common malignant tumor in China, and most of the patients have a background of chronic HBV infection. Nucleos(t)ide drugs (NAs) are currently recommended by major guidelines as a first-line treatments for chronic hepatitis B. However, it is still clinically possible to observe that some patients who have acquired virological response (HBV DNA below the lower detection limit) after NAS treatment progress to HCC, and its mechanism of development is still unclear. In this review, the mechanism relevant to HCC progression in treatment of chronic hepatitis B patients with NAs is analyzed mainly from the aspects of gene integration and persistent inflammatory injury.
- Published
- 2019
- Full Text
- View/download PDF
14. A case of entecavir-induced Fanconi syndrome.
- Author
-
Fujii T, Kawasoe K, Ohta A, and Nitta K
- Subjects
- Acidosis etiology, Acute Kidney Injury blood, Acute Kidney Injury complications, Acute Kidney Injury pathology, Adenine analogs & derivatives, Adenine therapeutic use, Aged, Alanine, Antiviral Agents therapeutic use, Fanconi Syndrome blood, Fanconi Syndrome drug therapy, Fanconi Syndrome urine, Guanine adverse effects, Guanine toxicity, Hepatitis B, Chronic drug therapy, Humans, Hypokalemia etiology, Hypophosphatemia etiology, Male, Nucleosides adverse effects, Tenofovir analogs & derivatives, Treatment Outcome, Withholding Treatment, Acute Kidney Injury chemically induced, Fanconi Syndrome chemically induced, Guanine analogs & derivatives, Hepatitis B, Chronic complications, Nucleosides toxicity
- Abstract
Acquired Fanconi syndrome has been associated with the long-term ingestion of several nucleoside analogs used to treat chronic hepatitis B virus infection. However, the nucleoside analog entecavir has not been found to cause nephrotoxicity. We report a case of entecavir-induced Fanconi syndrome. Our patient was a 73-year-old man admitted to our hospital because of renal dysfunction. He also presented with hyperaminoaciduria, renal diabetes, phosphaturia, hypophosphatemia, hypokalemia, hypouricemia, and hyperchloremic metabolic acidosis, supporting a diagnosis of Fanconi syndrome. In this case, the cause of Fanconi syndrome was most likely entecavir, which had been administered as needed depending on his renal function for 5 years. After drug discontinuation and replacement with tenofovir alafenamide fumarate therapy once a week, the patient's kidney function recovered and electrolyte anomalies partially improved. We highlight the fact that entecavir may induce severe renal dysfunction, which can cause the development of Fanconi syndrome; therefore, close monitoring of proximal tubular function is recommended during entecavir therapy.
- Published
- 2019
- Full Text
- View/download PDF
15. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis.
- Author
-
Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M, and Liu H
- Subjects
- Animals, Cats, Female, Male, Feline Infectious Peritonitis drug therapy, Nucleosides adverse effects, Nucleosides therapeutic use
- Abstract
Objectives: The aim of this study was to determine the safety and efficacy of the nucleoside analog GS-441524 for cats suffering from various forms of naturally acquired feline infectious peritonitis (FIP)., Methods: Cats ranged from 3.4-73 months of age (mean 13.6 months); 26 had effusive or dry-to-effusive FIP and five had non-effusive disease. Cats with severe neurological and ocular FIP were not recruited. The group was started on GS-441524 at a dosage of 2.0 mg/kg SC q24h for at least 12 weeks and increased when indicated to 4.0 mg/kg SC q24h., Results: Four of the 31 cats that presented with severe disease died or were euthanized within 2-5 days and a fifth cat after 26 days. The 26 remaining cats completed the planned 12 weeks or more of treatment. Eighteen of these 26 cats remain healthy at the time of publication (OnlineFirst, February 2019) after one round of treatment, while eight others suffered disease relapses within 3-84 days. Six of the relapses were non-neurological and two neurological. Three of the eight relapsing cats were treated again at the same dosage, while five cats had the dosage increased from 2.0 to 4.0 mg/kg q24h. The five cats treated a second time at the higher dosage, including one with neurological disease, responded well and also remain healthy at the time of publication. However, one of the three cats re-treated at the original lower dosage relapsed with neurological disease and was euthanized, while the two remaining cats responded favorably but relapsed a second time. These two cats were successfully treated a third time at the higher dosage, producing 25 long-time survivors. One of the 25 successfully treated cats was subsequently euthanized due to presumably unrelated heart disease, while 24 remain healthy., Conclusions and Relevance: GS-441524 was shown to be a safe and effective treatment for FIP. The optimum dosage was found to be 4.0 mg/kg SC q24h for at least 12 weeks.
- Published
- 2019
- Full Text
- View/download PDF
16. CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.
- Author
-
Higashi-Kuwata N, Hayashi S, Das D, Kohgo S, Murakami S, Hattori SI, Imoto S, Venzon DJ, Singh K, Sarafianos SG, Tanaka Y, and Mitsuya H
- Subjects
- Animals, Antiviral Agents adverse effects, Cell Line, Tumor, DNA Replication drug effects, Drug Discovery, Drug Resistance, Viral, Guanine analogs & derivatives, Guanine pharmacology, Hep G2 Cells, Humans, Mice, Nucleosides adverse effects, Purines adverse effects, Reverse Transcriptase Inhibitors adverse effects, Serum Albumin analysis, Antiviral Agents pharmacology, Hepatitis B drug therapy, Hepatitis B virus drug effects, Nucleosides pharmacology, Purines pharmacology, Reverse Transcriptase Inhibitors pharmacology
- Abstract
We designed, synthesized, and characterized a novel nucleoside analog, (1 S ,3 S ,5 S )-3-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-5-hydroxy-1-(hydroxymethyl)-2-methylene-cyclopentanecarbonitrile, or 4'-cyano-methylenecarbocyclic-2'-deoxyguanosine (CMCdG), and evaluated its anti-hepatitis B virus (anti-HBV) activity, safety, and related features. CMCdG's in vitro activity was determined using quantitative PCR and Southern blotting assays, and its cytotoxicity was determined with a 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay, while its in vivo activity and safety were determined in human liver-chimeric mice infected with wild-type HBV genotype Ce (HBV
WT Ce ) and an entecavir (ETV)-resistant HBV variant containing the amino acid substitutions L180M, S202G, and M204V (HBVETV-R L180M/S202G/M204V ). CMCdG potently inhibited HBV production in HepG2.2.15 cells (50% inhibitory concentration [IC50 ], ∼30 nM) and HBVWT Ce plasmid-transfected Huh7 cells (IC50 , 206 nM) and efficiently suppressed ETV-resistant HBVETV-R L180M/S202G/M204V (IC50 , 2,657 nM), while it showed no or little cytotoxicity (50% cytotoxic concentration, >500 μM in most hepatocytic cells examined). Two-week peroral administration of CMCdG (1 mg/kg of body weight/day once a day [q.d.]) to HBVWT Ce -infected human liver-chimeric mice reduced the level of viremia by ∼2 logs. CMCdG also reduced the level of HBVETV-R L180M/S202G/M204V viremia by ∼1 log in HBVETV-R L180M/S202G/M204V -infected human liver-chimeric mice, while ETV (1 mg/kg/day q.d.) completely failed to reduce the viremia. None of the CMCdG-treated mice had significant drug-related changes in body weights or serum human albumin levels. Structural analyses using homology modeling, semiempirical quantum methods, and molecular dynamics revealed that although ETV triphosphate (TP) forms good van der Waals contacts with L180 and M204 of HBVWT Ce reverse transcriptase (RT), its contacts with the M180 substitution are totally lost in the HBVETV-R L180M/S202G/M204V RT complex. However, CMCdG-TP retains good contacts with both the HBVWT Ce RT and HBVETV-R L180M/S202G/M204V RT complexes. The present data warrant further studies toward the development of CMCdG as a potential therapeutic for patients infected with drug-resistant HBV and shed light on the further development of more potent and safer anti-HBV agents., (Copyright © 2019 American Society for Microbiology.)- Published
- 2019
- Full Text
- View/download PDF
17. Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients.
- Author
-
Suárez E, Buti M, Rodríguez M, Prieto M, Pascasio-Acevedo JM, Casanovas T, Crespo J, Tapiador JAR, Gómez-Rodríguez R, Figueruela B, Diago M, Morillas RM, Zozaya JM, Calleja JL, Casado M, Molina E, Fuentes J, and Simón MA
- Subjects
- Adult, Antiviral Agents adverse effects, Biomarkers blood, Drug Administration Schedule, Female, Hepatitis B virus immunology, Hepatitis B, Chronic blood, Hepatitis B, Chronic ethnology, Hepatitis B, Chronic virology, Humans, Male, Middle Aged, Nucleosides adverse effects, Nucleotides adverse effects, Recurrence, Remission Induction, Retrospective Studies, Risk Factors, Spain epidemiology, Time Factors, Treatment Outcome, Antiviral Agents administration & dosage, Hepatitis B Surface Antigens blood, Hepatitis B virus drug effects, Hepatitis B, Chronic drug therapy, Nucleosides administration & dosage, Nucleotides administration & dosage, White People
- Abstract
Objective: The objective of this study was to determine the long-term clinical outcome and persistence of hepatitis B surface antigen (HBsAg) loss after discontinuation of treatment., Background: The prognosis of patients with chronic hepatitis B (CHB) treated with nucleos(t)ide analogues (NAs) who discontinue treatment after loss of HBsAg remains largely unknown, particularly in White patients., Patients and Methods: We analysed a cohort of patients with CHB who discontinued NA treatment after loss of HBsAg. A total of 69 patients with hepatitis-B-e antigen-positive or hepatitis-B-e antigen-negative CHB with undetectable HBsAg during NA treatment were included after discontinuation of treatment, and followed up for a median period of 37.8 months (interquartile range: 23.8-54.6 months)., Results: At the end of follow-up, none of the patients showed spontaneous reappearance of HBsAg and only one patient had detectable hepatitis B virus DNA (22 IU/ml). Another patient negative for HBsAg and anti-HBs developed hepatitis B virus reactivation without elevated transaminases after treatment with corticosteroids and vincristine for dendritic cell neoplasm, 38 months after withdrawal of the antiviral treatment. Regarding clinical outcome, a patient with cirrhosis developed hepatocellular carcinoma, 6.6 years after discontinuing treatment. None of the patients had hepatic decompensation or underwent liver transplantation., Conclusion: HBsAg clearance after discontinuing NAs in patients with CHB is persistent and associated with good prognosis. The risk for developing hepatocellular carcinoma persists among patients with cirrhosis.
- Published
- 2019
- Full Text
- View/download PDF
18. High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs.
- Author
-
Lin CC, Bair MJ, Liu CY, Lin ZY, Chen CJ, Chen MJ, Chu CH, Wang HY, Shih SC, and Wang TE
- Subjects
- Adult, Carcinoma, Hepatocellular diagnosis, Carcinoma, Hepatocellular virology, Early Detection of Cancer methods, Female, Follow-Up Studies, Guanine adverse effects, Guanine analogs & derivatives, Hepatitis B, Chronic complications, Humans, Lamivudine adverse effects, Liver Cirrhosis virology, Liver Neoplasms diagnosis, Liver Neoplasms virology, Male, Middle Aged, Retrospective Studies, Risk Factors, Telbivudine adverse effects, alpha-Fetoproteins analysis, Antiviral Agents adverse effects, Carcinoma, Hepatocellular chemically induced, Hepatitis B, Chronic drug therapy, Liver Neoplasms chemically induced, Nucleosides adverse effects
- Abstract
Nucleos(t)ide analogs are used for preventing liver cirrhosis in chronic hepatitis B patients, but the risk factors of hepatocellular carcinoma (HCC) in these patients remain unclear. We designed this retrospective cohort study, the aim is to determine the risk factors for HCC development and its image presentation under nucleos(t)ide analogs treatment.In this study, patients were treated with lamivudine (LAM), entecavir 0.5 mg (ETV), or telbivudine (LdT), and followed-up for at least 2 years to detect HCC and its presentation. Assessment of the risk factors for HCC included age, sex, HBeAg, viral load, liver cirrhosis, current and previous medications, and liver function tests.Totally, 396 patients were recruited, and 18 patients developed HCC. The mean time from the treatment to HCC development was 28.5 ± 16.7 months. The clinical characteristics in HCC and no-HCC groups showed significant differences among age (52.8 ± 6.1 vs 47.1 ± 12.6 years, P <.01), baseline alanine transaminase (ALT) levels (161.4 ± 177.3 vs 361.7 ± 496.3, P <.01), and baseline liver cirrhosis (72.2% vs 29.9%, P <.01). In patients aged ≥45 years, the hazard ratio of HCC was 10.2 and liver cirrhosis was 4.1. Majority of HCCs developed in the right liver (14/18), were single numbered (13/18), had tumor size about 1.9 ± 0.7 cm, were classified as T1 (14/18, TNM staging), and the atypical image occupied 88% of the HCC cases.The patients aged ≧45 years on long-term nucleos(t)ide analog therapy, and with baseline liver cirrhosis were at a high risk of HCC. Regular alpha-fetoprotein (AFP) assessment and image study of these patients are the gold standards for early HCC detection in patients with high percentage atypical HCC appearances.
- Published
- 2019
- Full Text
- View/download PDF
19. Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients.
- Author
-
Cho YY, Lee JH, Chang Y, Nam JY, Cho H, Lee DH, Cho EJ, Lee DH, Yu SJ, Lee JM, Kim YJ, and Yoon JH
- Subjects
- Adult, Aged, Antiviral Agents adverse effects, Carcinoma, Hepatocellular epidemiology, Carcinoma, Hepatocellular etiology, DNA, Viral blood, Female, Follow-Up Studies, Hepatitis B, Chronic epidemiology, Humans, Liver Cirrhosis epidemiology, Liver Cirrhosis etiology, Liver Neoplasms epidemiology, Liver Neoplasms etiology, Male, Middle Aged, Nucleosides adverse effects, Proportional Hazards Models, Survival Rate, Treatment Outcome, Antiviral Agents therapeutic use, Hepatitis B, Chronic drug therapy, Hepatitis B, Chronic mortality, Nucleosides therapeutic use
- Abstract
Nucleot(s)ide analogues (NAs) reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients. However, the risk of HCC is reportedly higher for NA-treated patients than for patients in the inactive CHB phase. This study aimed to compare the long-term outcomes of CHB patients with NA-induced viral suppression and those of patients with inactive CHB. This retrospective study involved 1118 consecutive CHB patients whose HBV DNA level was continuously <2000 IU/mL during follow-up with/without antiviral agents. The patients were classified into inactive CHB (n = 373) or NA groups (n = 745). The primary endpoint was overall survival. Secondary endpoints included development of HCC and other liver-related events. The median duration of follow-up was 41.0 (interquartile range = 26.5-55.0) months. The difference in overall survival between the NA group vs. the inactive CHB group was not significant (hazard ratio [HR] = 0.78; 95% confidence interval [CI] = 0.33-1.85; P = .57). The NA group showed a significantly higher risk of HCC (HR = 3.44; 95% CI = 1.82-6.52; P < .01), but comparable risk for non-HCC liver-related events (HR = 1.02; 95% CI = 0.66-1.59; P = .93), compared with the inactive CHB group. Among patients with cirrhosis, the NA group showed a significantly lower risk of death (HR = 0.31; 95% CI = 0.097-0.998; P = .05) and non-HCC liver-related events (HR = 0.51; 95% CI = 0.31-0.83; P < .01), but a slightly higher risk of HCC (HR = 2.39; 95% CI = 0.85-6.75; P = .09), compared to the inactive CHB group. The overall survival of untreated patients with inactive CHB and of CHB patients achieving viral suppression with NA was comparable. However, NA treatment of cirrhotic patients was significantly associated with longer overall survival and lower risk of liver-related events., (© 2018 John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
20. Serum NGAL can act as an early renal safety biomarker during long-term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B.
- Author
-
Carey I, Byrne R, Childs K, Horner M, Bruce M, Wang B, Dusheiko G, and Agarwal K
- Subjects
- Adult, Age Factors, Aged, Antiviral Agents therapeutic use, Biomarkers blood, Biomarkers urine, Creatinine blood, Early Diagnosis, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Nucleosides adverse effects, Nucleosides therapeutic use, Nucleotides adverse effects, Nucleotides therapeutic use, Proteinuria urine, ROC Curve, Renal Insufficiency etiology, Retrospective Studies, Young Adult, Antiviral Agents adverse effects, Hepatitis B, Chronic drug therapy, Lipocalin-2 blood, Renal Insufficiency diagnosis
- Abstract
Tubular renal toxicity is a side-effect of long-term therapy with nucleos(t)ide analogue(s) (NA) in chronic hepatitis B (CHB). There are no established surrogate markers in plasma of early NA-related toxicity. Neutrophil gelatinase-associated lipocalin (NGAL) is a protein produced by tubular cells following renal damage. We aimed therefore to retrospectively compare conventional renal markers (estimated glomerular filtration rates (eGFR) and urinary protein/creatinine ratio uPCR) with a sensitive biomarker (NGAL) in CHB patients on long-term NA therapy and assess the ability of new markers to predict NA-related renal toxicity (new onset of nonalbumin proteinuria). A total of 192 naïve CHB patients (median age 41 years, 78% males, 25% HBeAg+, 35% cirrhosis) were NA treated for at least 5 years (median 8.34 years, range 5.54-11.1 years). The eGFR and uPCR were compared at baseline and last clinical visit with serum NGAL concentrations measured by ELISA at same time-points and assessed according to the presence/absence of nonalbumin proteinuria at last visit. While baseline and last visit eGFR were similar (median:78 vs 84 mL/min), serum NGAL concentrations increased during therapy (median:9.4 vs 16.4 ng/mL, P < .05). The proportion of patients with proteinuria (uPCR > 15) increased between baseline and last visit (4.6% vs 21.4%, P < .05), with 30 (16%) patients having de novo nonalbumin proteinuria at last visit. High baseline NGAL concentrations were exclusive to patients with de novo nonalbumin proteinuria (median:31.7 vs 7.8 ng/mL, P < .01) and baseline NGAL levels >25 mg/mL were predictive of nonalbumin proteinuria at last visit (AUROC = 0.813). In conclusion, serum NGAL can act as a surrogate marker of early renal injury (de novo nonalbumin proteinuria) in CHB on long-term NA therapy., (© 2018 John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
21. Effect of Nucleos(t)ide Analogue Therapy on Risk of Intrahepatic Cholangiocarcinoma in Patients With Chronic Hepatitis B.
- Author
-
Lee TY, Hsu YC, Yu SH, Lin JT, Wu MS, and Wu CY
- Subjects
- Adult, Aged, Animals, Antiviral Agents therapeutic use, Female, Humans, Incidence, Male, Middle Aged, Nucleosides therapeutic use, Nucleotides therapeutic use, Retrospective Studies, Risk Assessment, Taiwan epidemiology, Antiviral Agents adverse effects, Cholangiocarcinoma epidemiology, Hepatitis C, Chronic complications, Hepatitis C, Chronic drug therapy, Nucleosides adverse effects, Nucleotides adverse effects
- Abstract
Background & Aims: Chronic infection with hepatitis B virus (HBV) increases risk of intrahepatic cholangiocarcinoma (ICC), but it is not clear whether antiviral therapy reduces risk. We investigated the association between nucleos(t)ide analogue therapy and ICC risk., Methods: We performed a nationwide long-term cohort study using Taiwan's National Health Insurance Research Database to obtain data on 185,843 patients with chronic HBV infection from October 1, 2003 through December 31, 2012. We excluded patients with confounding disorders such as infection with hepatitis C virus, HIV, or other hepatitis-associated viruses; liver flukes; biliary stone diseases; cholangitis; congenital biliary anomalies; biliary tract surgeries; or cancer. We identified 10,062 patients who received nucleos(t)ide analogue therapy (the treated group), and used propensity scores to match them (1:1) with patients who received hepatoprotectants (the untreated group). Cumulative incidences of and hazard ratios (HRs) for ICC development were analyzed., Results: The cumulative incidence of ICC was significantly lower in the treated group after 3 years of therapy (1.28%; 95% CI, 0.56-2.01) than in the untreated group (3.14%; 95% CI, 2.02-4.27) and after 5 years of therapy (1.53%; 95% CI, 0.73-2.33 vs 4.32% in untreated group; 95% CI, 2.96-5.6869). In multivariable regression analysis, nucleos(t)ide analogue therapy was independently associated with a reduced risk of ICC (HR, 0.44; 95% CI, 0.25-0.78; P = .005). Older age (HR 1.05 per year; 95% CI, 1.03-1.07) and cirrhosis (HR, 2.80; 95% CI, 1.52-5.1415) were independently associated with an increased risk of ICC. Sensitivity analyses verified the association between nucleos(t)ide analogue therapy and a reduced ICC risk., Conclusion: A nationwide long-term cohort study in Taiwan showed that nucleos(t)ide analogue therapy for chronic HBV infection is significantly associated with a reduced ICC risk., (Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
22. [Chronic hepatitis B and D (delta) : Current and future treatments].
- Author
-
Wortmann N, Höner Zu Siederdissen C, and Cornberg M
- Subjects
- Hepatitis B Surface Antigens, Hepatitis B virus isolation & purification, Hepatitis B, Chronic virology, Hepatitis D virology, Hepatitis Delta Virus isolation & purification, Humans, Interferon-alpha adverse effects, Nucleosides adverse effects, Nucleosides therapeutic use, Nucleotides adverse effects, Nucleotides therapeutic use, Antiviral Agents therapeutic use, Hepatitis B virus drug effects, Hepatitis B, Chronic drug therapy, Hepatitis D drug therapy, Hepatitis Delta Virus drug effects, Interferon-alpha therapeutic use
- Abstract
Background: Worldwide, hepatitis B virus (HBV) infection is among the 30 leading causes of death, despite effective vaccination and therapeutic options. Chronic hepatitis delta (coinfection with hepatitis D virus) leads to a rapid disease progression., Aims: Based on current international guidelines and studies, an overview about present and future therapeutic options for chronic hepatitis B and delta is provided., Results: Therapy with nucleoside or nucleotide analogues leads to nearly complete HBV DNA suppression, which is associated with regression of liver fibrosis and a lower risk for the development of hepatocellular carcinoma. Therapy of chronic hepatitis delta with pegylated interferon alfa achieves only low response rates with high risk for virological relapse. Various therapeutic approaches are currently being investigated in preclinical and clinical studies and have led to a significant reduction of hepatitis B surface antigen (HBsAg) and HDV RNA., Conclusion: Current therapies of chronic HBV infection can effectively reduce subsequent complications. New therapeutic approaches promise functional cure (HBsAg loss) of HBV infection and effective treatment options for patients with chronic hepatitis delta.
- Published
- 2018
- Full Text
- View/download PDF
23. A Dynamic Model for Predicting Outcome in Patients with HBV Related Acute-On-Chronic Liver Failure.
- Author
-
Lin W, Zhang J, Liu X, Liu H, He J, Li M, Zhang S, Zhang Y, Chen H, Zhang C, Wu W, Jin C, Lee SS, and Duan Z
- Subjects
- Acute-On-Chronic Liver Failure diagnosis, Acute-On-Chronic Liver Failure mortality, Acute-On-Chronic Liver Failure virology, Adult, Antiviral Agents adverse effects, Bilirubin blood, Biomarkers blood, China, Disease Progression, Female, Hepatitis B Antibodies blood, Hepatitis B e Antigens immunology, Hepatitis B virus immunology, Hepatitis B virus pathogenicity, Hepatitis B, Chronic diagnosis, Hepatitis B, Chronic mortality, Hepatitis B, Chronic virology, Humans, Male, Middle Aged, Nucleosides adverse effects, Organ Dysfunction Scores, Predictive Value of Tests, Prospective Studies, Prothrombin metabolism, Reproducibility of Results, Time Factors, Treatment Outcome, Acute-On-Chronic Liver Failure drug therapy, Antiviral Agents therapeutic use, Decision Support Techniques, Hepatitis B virus drug effects, Hepatitis B, Chronic drug therapy, Models, Biological, Nucleosides therapeutic use
- Abstract
Introduction and Aim: Accurately predicting the prognosis of individual patient is crucial in the management of ACLF. We aimed to establish a specific prognostic model for HBV-related ACLF patients treated with nucleoside analog (NA)., Material and Methods: We prospectively collected 205 ACLF cases diagnosed according to the APASL criteria. A dynamic prognostic model based on APASL criteria was established and validated. To demonstrate that the model is also applicable to those within EASL criteria, we divided the patients into two groups: met APASL criteria only (group A, n = 123); met both APASL and EASL criteria (group B, n = 82). Its prognostic accuracy was also compared with chronic liver failure-sequential organ failure assessment (CLIF-SOFA) score in group B., Results: The model is: R = 0.94 x Bilirubin + 0.53 x evolution of Bilirubin - 0.45 x PT-A - 0.22 x evolution in PT-A -0.1 x PLT + 10 x anti-HBe. The area under receiver operating characteristic curve (AUC) of the model for predicting 90-day mortality was 0.86, which was significantly higher than that of model for end stage liver disease(MELD), MELD-Na, CLIF-SOFA, ΔMELD (7d) and ΔMELD-Na (7d), ΔCLIF- SOFA(7d) (all p < 0.01). The AUC of our model in the validation group was 0.79 which was superior to MELD (0.45) CLIF-SOFA (0.53) score in group B patients (p < 0.01)., Conclusion: In conclusion, the model was superior to the conventional methods in predicting the outcomes of patients with HBV related ACLF treated with NA. It is the first description of a novel prognostic model using consecutive data in patients with HBV-induced acute-on-chronic liver failure (ACLF) treated by nucleoside analogs.
- Published
- 2018
- Full Text
- View/download PDF
24. Nucleoside reverse transcriptase inhibitors induced hepatocellular mitochondrial DNA lesions and compensatory enhancement of mitochondrial function and DNA repair.
- Author
-
Liang Q, Zeng J, Wu J, Qiao L, Chen Q, Chen D, and Zhang Y
- Subjects
- Adult, Aged, Animals, Anti-HIV Agents therapeutic use, Autopsy, Female, Humans, Liver pathology, Male, Mice, Inbred BALB C, Middle Aged, Models, Animal, Nucleosides therapeutic use, Reverse Transcriptase Inhibitors therapeutic use, Young Adult, Anti-HIV Agents adverse effects, DNA Damage drug effects, DNA Repair, DNA, Mitochondrial drug effects, Hepatocytes drug effects, Nucleosides adverse effects, Reverse Transcriptase Inhibitors adverse effects
- Abstract
Nucleoside reverse transcriptase inhibitors (NRTIs) are the backbone of combined antiretroviral therapy (cART) and are widely used in anti-human immunodeficiency virus (HIV) therapy. Long-term administration of NRTIs can result in mitochondrial dysfunction in certain HIV-1-infected patients. However, NRTI-associated liver mitochondrial toxicity is not well known. Herein, the liver autopsy of acquired immune deficiency syndrome (AIDS) patients and the liver tissues of mice with 12 months of NRTI exposure were used to identify NRTI-associated liver toxicity with immunofluorescence, quantitative real-time polymerase chain reaction (qPCR), Amplex red and horseradish peroxidase, and cloning and sequencing. Laser capture microdissection was used to capture hepatocytes from liver tissues. We observed DNA oxidative damage and mitochondrial DNA (mtDNA) loss in the livers of AIDS patients, and cART patients had higher DNA oxidative damage and lower DNA repair function in liver tissues than non-cART patients. We also observed liver oxidative damage, increased DNA repair and mtDNA loss in mice with exposure to four different NRTIs for 12 months, and hepatocytes had no more mtDNA loss than liver tissues. Although NRTIs could induce mitochondrial hydrogen peroxide production, increased mitochondrial oxygen consumption was found with a Clark-type electrode. The captured hepatocytes had greater diversity in their mtDNA D-loop, dehydrogenase subunit1 (ND1) and ND4 than the controls. Long-term NRTI exposure induced single nucleotide variation in hepatocellular mtDNA D-loop, ND1 and ND4. Our findings indicate that NRTIs can induce liver mtDNA lesions, but simultaneously enhance mitochondrial function and mtDNA repair., (Copyright © 2017. Published by Elsevier B.V.)
- Published
- 2018
- Full Text
- View/download PDF
25. Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B.
- Author
-
Wong GL, Seto WK, Wong VW, Yuen MF, and Chan HL
- Subjects
- Administration, Oral, Drug-Related Side Effects and Adverse Reactions epidemiology, Female, Hepatitis B, Chronic epidemiology, Humans, Male, Nucleosides administration & dosage, Nucleosides adverse effects, Nucleosides analogs & derivatives, Pregnancy, Renal Insufficiency chemically induced, Renal Insufficiency epidemiology, Time Factors, Treatment Outcome, Antiviral Agents administration & dosage, Antiviral Agents adverse effects, Hepatitis B, Chronic drug therapy
- Abstract
Background: Safety profile of nucleos(t)ide analogues is an important issue in view of its widespread use for decades in patients with chronic hepatitis B (CHB)., Aim: To review and evaluate the latest evidence on the safety profiles of the six approved nucleoside analogues., Methods: Relevant articles related to nucleoside analogue safety were selected for review following extensive language- and date-unrestricted, electronic searches of the literature., Results: Nephrotoxicity has been well reported in patients receiving older generations of nucleotide analogues, namely adefovir dipivoxil and tenofovir disoproxil fumarate (TDF). Yet risks of renal failure and renal replacement therapy were similar in patients treated with nucleoside analogues versus nucleotide analogues in real-life setting. Bone toxicity is closely related to nucleoside analogue effect on renal proximal tubular and phosphaturia. Real-life data demonstrated increased risk of hip fracture in patients receiving adefovir but not TDF. The newly approved tenofovir alafenamide (TAF) has improved renal and bone safety profiles compared to TDF. Long-term use of nucleoside analogues eg entecavir does not increase the risk of other cancers. Muscular toxicity may be seen in telbivudine-treated patients so regular monitoring is advised. Peripheral neuropathy and lactic acidosis are rare adverse events. Latest international guidelines support the use of TDF, telbivudine and lamivudine during pregnancy; breastfeeding is not contraindicated during TDF therapy., Conclusions: Long-term safety profile of nucleoside analogues is now better defined with more data from large real-life cohorts and clinical trials with long-term follow-up. The new nucleotide analogue, TAF is now available with favourable renal and bone safety profiles., (© 2018 John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
26. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.
- Author
-
Buti M, Riveiro-Barciela M, and Esteban R
- Subjects
- Adenine analogs & derivatives, Administration, Oral, Alanine, Drug-Related Side Effects and Adverse Reactions epidemiology, Guanine analogs & derivatives, Humans, Nucleosides adverse effects, Nucleosides analogs & derivatives, Randomized Controlled Trials as Topic, Tenofovir, Time Factors, Treatment Outcome, Antiviral Agents adverse effects, Antiviral Agents therapeutic use, Hepatitis B, Chronic drug therapy, Nucleosides therapeutic use
- Abstract
Long-term treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogues is often necessary to achieve durable viral suppression. Therefore, current guidelines recommend the most potent drugs with optimal resistance profiles. Entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are the first-line monotherapies for CHB. All of these drugs are highly effective in suppressing viral replication but with slightly different safety profiles. This review provides an overview of the long-term efficacy and safety data that have become available over the 10 years since ETV and TDF were first approved for the treatment of chronic hepatitis, and recent data on TAF in patients with CHB., (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
27. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B.
- Author
-
van Bömmel F and Berg T
- Subjects
- Antiviral Agents adverse effects, DNA, Viral blood, Drug Administration Schedule, Hepatitis B e Antigens blood, Hepatitis B virus genetics, Humans, Nucleosides adverse effects, Nucleosides analogs & derivatives, Patient Selection, Randomized Controlled Trials as Topic, Recurrence, Treatment Outcome, Withholding Treatment, Antiviral Agents therapeutic use, Hepatitis B Surface Antigens blood, Hepatitis B, Chronic drug therapy, Nucleosides therapeutic use
- Abstract
The immune response against the infection is impaired in patients with chronic hepatitis B, and although HBV DNA can effectively be suppressed by nucleos(t)ide analogues (NA), durable immune control is only established in a minority of patients. This especially applies in HBeAg-negative patients who usually must receive lifelong NA treatment. Calculated withdrawal of NA leads to a relapse of HBV DNA in most patients. There is evidence that this sudden exposure of viral antigens can trigger immune control in some patients which may result in HBsAg loss or a form of immune control, then sustained low HBV DNA levels and normal alanine aminotransferase (ALT). In the first prospective randomized trial investigating tenofovir treatment cessation in HBeAg-negative patients, most patients did not need retreatment after NA cessation, although all patients showed a transient relapse in HBV DNA. HBsAg loss was identified in almost 20% nearly 3 years after stopping NA. Further confirmation of these findings is needed in larger randomized trials and patients who are most likely to benefit from finite therapy must be identified to individualize NA stopping strategies. However, these results suggest that in patients without risk factors such as cirrhosis or other severe conditions, NA treatment may be stopped, as long as adequate safety rules for retreatment are followed., (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
28. Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence.
- Author
-
Orkin C, Llibre JM, Gallien S, Antinori A, Behrens G, and Carr A
- Subjects
- Anti-HIV Agents adverse effects, Antiretroviral Therapy, Highly Active adverse effects, Drug Utilization, Humans, Nucleosides adverse effects, Randomized Controlled Trials as Topic, Reverse Transcriptase Inhibitors adverse effects, Treatment Outcome, Anti-HIV Agents administration & dosage, Antiretroviral Therapy, Highly Active methods, HIV Infections drug therapy, Nucleosides administration & dosage, Reverse Transcriptase Inhibitors administration & dosage
- Abstract
Antiretroviral (ARV) therapy, comprising a backbone of two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus another ARV, is the recognized standard of care (SOC), which has helped extend life expectancy in people living with HIV. In a quest to reduce lifelong drug exposure and minimize or avoid the toxicity of NRTIs, "NRTI-reducing" regimens have been investigated. This descriptive review assessing the results of NRTI-reducing strategies from the largest randomized trials focuses on virological efficacy, resistance, regimen safety (in terms of bone mineral density, renal function, lipids and central nervous system function) and simplicity. The review considers efficacy across various NRTI-sparing strategies, for example an integrase strand transfer inhibitor (INSTI) plus a ritonavir-boosted protease inhibitor (PI/r) or PI/r + lamivudine (3TC), in both naïve and switch regimes. Of 10 key studies in treatment-naïve adults assessing five NRTI-reducing strategies, only four studies demonstrated noninferiority vs. SOC [GARDEL, NEAT 001, AIDS Clinical Trials Group 5142 and PROGRESS]. In switch settings, 17 studies (10 randomized) were reviewed that used four strategies, including three studies assessing an INSTI plus a nonnucleoside reverse transcriptase inhibitor . Noninferiority of the NRTI-reducing arm was shown in six of 10 studies (ATLAS-M, SALT, DUAL, OLE, LATTE-2 and SWORD). In general, NRTI-reducing therapy did not always result in an improvement in short- or long-term adverse events; however, in many cases, these endpoints were not reported. Some of these studies reported higher virological failure rates with more frequent emergence of resistance mutations. None of these NRTI-reducing strategies has been compared against a single-pill regimen, including those containing tenofovir alafenamide. Only strategies demonstrating noninferior efficacy, a benefit in safety/tolerability, and a favourable cost-efficacy ratio, preferably in a single pill, will eventually match the current SOC of triple ARV therapy., (© 2017 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.)
- Published
- 2018
- Full Text
- View/download PDF
29. Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients.
- Author
-
Simonetti G, Gitto S, Golfieri L, Gamal N, Loggi E, Taruschio G, Cursaro C, Nunzella S, Grandi S, and Andreone P
- Subjects
- Adult, Age Factors, Aged, Antiviral Agents adverse effects, Biomarkers blood, Chi-Square Distribution, Cross-Sectional Studies, Female, Hepatitis B psychology, Hepatitis B virology, Hepatitis B virus growth & development, Hepatitis B virus immunology, Humans, Italy, Logistic Models, Male, Middle Aged, Multivariate Analysis, Nucleosides adverse effects, Nucleotides adverse effects, Prospective Studies, Risk Factors, Surveys and Questionnaires, Time Factors, Treatment Outcome, Antiviral Agents therapeutic use, Hepatitis B blood, Hepatitis B drug therapy, Hepatitis B Surface Antigens blood, Hepatitis B virus drug effects, Nucleosides therapeutic use, Nucleotides therapeutic use, Quality of Life, Sustained Virologic Response, Virus Replication drug effects
- Abstract
Objective: Hepatitis B virus infection is a relevant health problem with more than 400 million infected people worldwide. Our aim was to analyze quality of life of hepatitis B virus surface antigen-positive patients in inactive status or treated with antivirals., Patients and Methods: Patients referred to our center between February and October 2016 were prospectively enrolled. Half-structured interview was used for examining psychological symptoms and Illness Behavior Questionnaire for exploring attitudes toward illness. We used World Health Organization Quality of Life-short version survey for studying quality of life and logistic regression to find possible predictors of nonadequate quality of life., Results: The study involved 102 patients. At Illness Behavior Questionnaire test, psychological perception of illness (21.6%), and denial of illness itself (13.7%) were the most frequent conditions. Inactive and treated subgroups were comparable for almost all variables and scores, but patients on treatment were significantly more often male, older, and cirrhotic. Sleep disturbance emerged as an independent predictor of inadequate quality of life in Physical health, anxiety in Social relationship, and both anxiety and hostility in Environmental health domain., Conclusion: Inactive carriers and patients on treatment showed the same global quality of life, but the second group was older and more frequently with an advanced liver disease. Further studies might specifically evaluate the impact of antiviral therapy on quality of life.
- Published
- 2018
- Full Text
- View/download PDF
30. Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation.
- Author
-
Fung J, Wong T, Chok K, Chan A, Sin SL, Cheung TT, Dai WC, Ng K, Ng K, Man K, Seto WK, Lai CL, Yuen MF, and Lo CM
- Subjects
- Administration, Oral, Adult, Aged, Antiviral Agents adverse effects, DNA, Viral genetics, Drug Administration Schedule, End Stage Liver Disease diagnosis, End Stage Liver Disease mortality, End Stage Liver Disease virology, Female, Genotype, Graft Survival drug effects, Hepatitis B virus genetics, Hepatitis B, Chronic diagnosis, Hepatitis B, Chronic mortality, Hepatitis B, Chronic virology, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Nucleosides adverse effects, Nucleotides adverse effects, Recurrence, Risk Factors, Time Factors, Treatment Outcome, Viral Load, Virus Activation drug effects, Antiviral Agents administration & dosage, Drug Resistance, Viral genetics, End Stage Liver Disease surgery, Hepatitis B virus drug effects, Hepatitis B, Chronic drug therapy, Lamivudine administration & dosage, Liver Transplantation adverse effects, Liver Transplantation mortality, Mutation, Nucleosides administration & dosage, Nucleotides administration & dosage
- Abstract
Background: There is currently limited data regarding the use of oral antiviral therapy alone without hepatitis B immune globulin for chronic hepatitis B patients with preexisting lamivudine (LAM) resistance (LAM-R) undergoing liver transplantation., Methods: This is a cohort study determining the effectiveness and long-term outcome in this group of patients., Results: Fifty-seven consecutive chronic hepatitis B patients with preexisting rt204 LAM-R mutations or virological load refractory to LAM undergoing liver transplantation were included, with a median follow-up of 73 months. Fifty-five (96.5%) patients received a regimen that included the use of nucleotide analogs. The cumulative rate of hepatitis B surface antigen seroclearance at 1, 5, and 10 years was 82%, 88%, and 91%, respectively. At the time of transplantation, 39 (72%) patients had detectable hepatitis B virus (HBV) DNA, with a median of 4.5 log copies/mL. The cumulative rate of HBV undetectability was 91% at 1 year, increasing to 100% by 5 years. After 1 year of liver transplantation, over 90% of the patients had undetectable HBV DNA, and from 8 years onward, 100% had undetectable HBV DNA. The overall long-term survival was excellent, with a 12-year survival of 87%. There was no HBV-related graft loss, and no retransplantation or deaths due to HBV reactivation., Conclusion: Oral antiviral therapy alone without hepatitis B immune globulin is highly effective in preventing HBV reactivation and graft loss from recurrent hepatitis B after liver transplantation in patients with preexisting LAM resistance HBV. The long-term outcome was excellent, with survival of 87% at 12 years after transplantation, without any mortality related to HBV reactivation.
- Published
- 2017
- Full Text
- View/download PDF
31. Efficacy and safety of nucleoside antiviral drugs for treatment of recurrent herpes labialis: a systematic review and meta-analysis.
- Author
-
Chen F, Xu H, Liu J, Cui Y, Luo X, Zhou Y, Chen Q, and Jiang L
- Subjects
- Antiviral Agents adverse effects, Humans, Nucleosides adverse effects, Recurrence, Antiviral Agents therapeutic use, Herpes Labialis drug therapy, Nucleosides therapeutic use, Simplexvirus drug effects
- Abstract
Objectives: To evaluate the effectiveness and safety of nucleoside antiviral drugs for the treatment of recurrent herpes labialis., Methods: Randomized controlled trials that examined the effectiveness and/or safety of nucleoside antiviral drugs for recurrent herpes labialis were identified via a literature search. The parameters used to measure efficacy were time to healing of classic and all lesions, time to resolution of pain, and percentage of aborted lesions. Safety was assessed by evaluating the adverse events reported during treatment. Subgroup analyses based on the mode of application (topical/systemic) and type of nucleoside antiviral drugs were performed, as were sensitivity analyses of studies with a low risk of bias., Results: Our analysis included 16 publications reporting 25 randomized controlled trials (8453 patients). Nucleoside antiviral drugs decreased the time to healing of all lesions (mean difference: -0.74 days; 95% confidence interval: -0.86, -0.62), especially classic lesions (mean difference: -1.09 days; 95% confidence interval: -1.27, -0.92). They also reduced the time to resolution of pain (mean difference: -0.38 days; 95% confidence interval: -0.58, -0.18) and increased the percentage of aborted lesions (rate ratio: 1.15; 95% confidence interval: 1.07, 1.23). Valaciclovir more effectively reduced the time to healing of all lesions and the time to resolution of pain than did aciclovir. Both nucleoside antiviral drugs increased the percentage of aborted lesions, whereas penciclovir and famciclovir did not., Conclusions: Nucleoside antiviral drugs are safe and beneficial for the treatment of recurrent herpes labialis; both systemic and topical formulations are recommended. Valaciclovir is more effective than aciclovir, especially in reducing the time to healing of lesions., (© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
32. SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.
- Author
-
Herold N, Rudd SG, Sanjiv K, Kutzner J, Bladh J, Paulin CBJ, Helleday T, Henter JI, and Schaller T
- Subjects
- Animals, Cell Death drug effects, Cell Line, Tumor, Disease Models, Animal, Gene Expression Regulation, Leukemic drug effects, Humans, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute pathology, Mice, Models, Biological, Neoplasms pathology, Nucleosides chemistry, RNA, Messenger genetics, RNA, Messenger metabolism, SAM Domain and HD Domain-Containing Protein 1 genetics, Antimetabolites adverse effects, Neoplasms drug therapy, Nucleosides adverse effects, Protective Agents pharmacology, Protective Agents therapeutic use, SAM Domain and HD Domain-Containing Protein 1 metabolism
- Abstract
Recently, we demonstrated that sterile α motif and HD domain containing protein 1 (SAMHD1) is a major barrier in acute myelogenous leukemia (AML) cells to the cytotoxicity of cytarabine (ara-C), the most important drug in AML treatment. Ara-C is intracellularly converted by the canonical dNTP synthesis pathway to ara-CTP, which serves as a substrate but not an allosteric activator of SAMHD1. Using an AML mouse model, we show here that wild type but not catalytically inactive SAMHD1 reduces ara-C treatment efficacy in vivo. Expanding the clinically relevant substrates of SAMHD1, we demonstrate that THP-1 CRISPR/Cas9 cells lacking a functional SAMHD1 gene showed increased sensitivity to the antimetabolites nelarabine, fludarabine, decitabine, vidarabine, clofarabine, and trifluridine. Within this Extra View, we discuss and build upon both these and our previously reported findings, and propose SAMHD1 is likely active against a variety of nucleoside analog antimetabolites present in anti-cancer chemotherapies. Thus, SAMHD1 may constitute a promising target to improve a wide range of therapies for both hematological and non-haematological malignancies.
- Published
- 2017
- Full Text
- View/download PDF
33. Effect of 48-week pegylated interferon α-2a or nucleos(t)ide analogue therapy on renal function in Chinese patients with chronic hepatitis B.
- Author
-
Zhang Y, Zhang WL, Pang XW, Wang LX, Wei X, Huang CX, Bai XF, Han S, Liu LN, and Lian JQ
- Subjects
- Antiviral Agents adverse effects, Asian People, Humans, Interferon-alpha adverse effects, Kidney physiology, Kidney Function Tests, Nucleosides adverse effects, Polyethylene Glycols adverse effects, Recombinant Proteins adverse effects, Recombinant Proteins therapeutic use, Retrospective Studies, Antiviral Agents therapeutic use, Hepatitis B, Chronic drug therapy, Interferon-alpha therapeutic use, Kidney drug effects, Nucleosides therapeutic use, Polyethylene Glycols therapeutic use
- Abstract
Background: Controversy remains as to whether antiviral agents contribute to renal dysfunction in patients with chronic hepatitis B virus (HBV) infection. Thus, the aim of study was to analyze the changes in renal function of chronic hepatitis B (CHB) patients in response to anti-HBV therapy and the association with treatments., Method: We performed a retrospective observational cohort study to investigate factors associated with renal function in 249 Chinese CHB patients who were treated with pegylated interferon α-2a (PEG-IFN-α-2a) or nucleos(t)ide analogues for 48 weeks. Changes of estimated glomerular filtration rate (eGFR), which was computed with both the Chronic Kidney Disease Epidemiology Collaboration and the Modification of Diet in Renal Disease formulas, were tested by repeated measures One-way analysis of variance within groups. A linear mixed effects model for repeated measures was also used to evaluate the association between baseline information and eGFR changes over time in all enrolled patients. The model considered the baseline age, sex, HBV DNA, aminotransferase, blood urea nitrogen, treatment group, time, and group-by-time interaction as fixed effects and incorporated random effects for individual subjects., Results: The eGFR increased in patients given PEG-IFN-α-2a, decreased in patients given adefovir, but remained stable in patients given entecavir. Age and blood urea nitrogen were significant negative predictive factors for eGFR changes., Conclusion: In real-life study, PEG-IFN-α-2a therapy in CHB patients increased eGFR, thus may associate with renoprotective effects when compared with adefovir or entecavir therapies.
- Published
- 2017
- Full Text
- View/download PDF
34. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
- Author
-
Bourlière M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, Thabut D, Guyader D, Hezode C, Picon M, Causse X, Leroy V, Bronowicki JP, Carrieri P, Riachi G, Rosa I, Attali P, Molina JM, Bacq Y, Tran A, Grangé JD, Zoulim F, Fontaine H, Alric L, Bertucci I, Bouvier-Alias M, and Carrat F
- Subjects
- Adolescent, Adult, Aged, Antiviral Agents adverse effects, Drug Administration Schedule, Female, Hepatitis B e Antigens blood, Hepatitis B, Chronic virology, Humans, Interferon-alpha adverse effects, Male, Middle Aged, Nucleosides adverse effects, Nucleosides therapeutic use, Nucleotides adverse effects, Nucleotides therapeutic use, Patient Reported Outcome Measures, Polyethylene Glycols adverse effects, Recombinant Proteins adverse effects, Recombinant Proteins therapeutic use, Young Adult, Antiviral Agents therapeutic use, DNA, Viral blood, Hepatitis B Surface Antigens blood, Hepatitis B virus genetics, Hepatitis B, Chronic blood, Hepatitis B, Chronic drug therapy, Interferon-alpha therapeutic use, Polyethylene Glycols therapeutic use
- Abstract
Background: Findings from uncontrolled studies suggest that addition of pegylated interferon in patients with HBe antigen (HBeAg)-negative chronic hepatitis B receiving nucleos(t)ide analogues with undetectable plasma hepatitis B virus (HBV) DNA might increase HBs antigen (HBsAg) clearance. We aimed to assess this strategy., Methods: In this randomised, controlled, open-label trial, we enrolled patients aged 18-75 years with HBeAg-negative chronic hepatitis B and documented negative HBV DNA while on stable nucleos(t)ide analogue regimens for at least 1 year from 30 hepatology tertiary care wards in France. Patients had to have an alanine aminotransferase concentration of less than or equal to five times the upper normal range, no hepatocellular carcinoma, and a serum α fetoprotein concentration of less than 50 ng/mL, normal dilated fundus oculi examination, and a negative pregnancy test in women. Patients with contraindications to pegylated interferon were not eligible. A centralised randomisation used computer-generated lists of random permuted blocks of four with stratification by HBsAg titres (< or ≥2·25 log
10 IU/mL) to allocate patients (1:1) to receive a 48 week course of subcutaneous injections of 180 μg per week of pegylated interferon alfa-2a in addition to the nucleos(t)ide analogue regimen or to continue to receive nucleos(t)ide analogues only. The primary endpoint was HBsAg loss at week 96 by intention-to-treat analysis. This trial is closed and registered with ClinicalTrials.gov, number NCT01172392., Findings: Between Jan 20, 2011, and July 18, 2012, we randomly allocated 185 patients (92 [50%] to pegylated interferon and nucleos(t)ide analogues and 93 [50%] to nucleos(t)ide analogues alone). We excluded two patients from the pegylated interferon plus nucleos(t)ide analogues group from analyses because of withdrawal of consent (one patient) or violation of inclusion criteria (one patient). At week 96, loss of HBsAg was reported in seven (7·8%) of 90 patients in the pegylated interferon plus nucleos(t)ide analogues group versus three (3·2%) of 93 in the nucleos(t)ide analogues-alone group (difference 4·6% [95% CI -2·6 to 12·5]; p=0·15). 85 (94%) of 90 patients started pegylated interferon, three (4%) of whom had a dose reduction and 17 (20%) had an early discontinuation of pegylated interferon (seven [41%] for serious adverse events). Grade 3 and 4 adverse events were more frequent in the pegylated interferon plus nucleos(t)ide analogues group (26 [29%] grade 3 adverse events; 19 [21%] grade 4 adverse events) than in the nucleos(t)ide analogues-alone group (three [3%] grade 3; six [6%] grade 4)., Interpretation: Addition of a 48 week course of pegylated interferon to nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B with undetectable HBV DNA for a least 1 year was poorly tolerated and did not result in a significant increase of HBsAg clearance., Funding: Institut national de la santé et de la recherche médicale-Agence nationale de recherches sur le sida et les hépatites virales (France Recherche Nord&sud Sida-vih Hepatites)., (Copyright © 2017 Elsevier Ltd. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
35. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
- Author
-
Wu PY, Cheng CY, Liu CE, Lee YC, Yang CJ, Tsai MS, Cheng SH, Lin SP, Lin DY, Wang NC, Lee YC, Sun HY, Tang HJ, and Hung CC
- Subjects
- Adult, Alanine Transaminase blood, Anti-HIV Agents therapeutic use, Aspartate Aminotransferases blood, CD4 Lymphocyte Count, Chemical and Drug Induced Liver Injury enzymology, Chemical and Drug Induced Liver Injury epidemiology, Disease Management, Drug Eruptions epidemiology, Drug Therapy, Combination, Female, Humans, Incidence, Male, Middle Aged, Nucleosides therapeutic use, RNA, Viral blood, Retrospective Studies, Reverse Transcriptase Inhibitors therapeutic use, Risk Factors, Severity of Illness Index, Taiwan epidemiology, Viral Load, Young Adult, Anti-HIV Agents adverse effects, Chemical and Drug Induced Liver Injury etiology, Drug Eruptions etiology, HIV Infections drug therapy, Nucleosides adverse effects, Reverse Transcriptase Inhibitors adverse effects, Viremia drug therapy
- Abstract
Objectives: Two nucleos(t)ide reverse-transcriptase inhibitors (NRTIs) plus 1 non-NRTI (nNRTI) remain the preferred or alternative combination antiretroviral therapy (cART) for antiretroviral-naive HIV-positive patients in Taiwan. The three most commonly used nNRTIs are nevirapine (NVP), efavirenz (EFV) and rilpivirine (RPV). This study aimed to determine the incidences of hepatotoxicity and skin rashes within 4 weeks of initiation of cART containing 1 nNRTI plus 2 NRTIs., Methods: Between June, 2012 and November, 2015, all antiretroviral-naive HIV-positive adult patients initiating nNRTI-containing cART at 8 designated hospitals for HIV care were included in this retrospective observational study. According to the national HIV treatment guidelines, patients were assessed at baseline, 2 and 4 weeks of cART initiation, and subsequently every 8 to 12 weeks. Plasma HIV RNA load, CD4 cell count and aminotransferases were determined. The toxicity grading scale of the Division of AIDS (DAIDS) 2014 was used for reporting clinical and laboratory adverse events., Results: During the 3.5-year study period, 2,341 patients initiated nNRTI-containing cART: NVP in 629 patients, EFV 1,363 patients, and RPV 349 patients. Rash of any grade occurred in 14.1% (n = 331) of the patients. In multiple logistic regression analysis, baseline CD4 cell counts (per 100-cell/μl increase, adjusted odds ratio [AOR], 1.125; 95% confidence interval [95% CI], 1.031-1.228) and use of NVP (AOR, 2.443; 95% CI, 1.816-3.286) (compared with efavirenz) were independently associated with the development of skin rashes. Among the 1,455 patients (62.2%) with aminotransferase data both at baseline and week 4, 72 (4.9%) developed grade 2 or greater hepatotoxicity. In multiple logistic regression analysis, presence of antibody for hepatitis C virus (HCV) (AOR, 2.865; 95% CI, 1.439-5.704) or hepatitis B surface antigen (AOR, 2.397; 95% CI, 1.150-4.997), and development of skin rashes (AOR, 2.811; 95% CI, 1.051-7.521) were independently associated with the development of hepatotoxicity., Conclusions: The baseline CD4 cell counts and use of NVP were associated with increased risk of skin rashes, while hepatotoxicity was independently associated with HCV or hepatitis B virus coinfection, and development of skin rashes in antiretroviral-naïve HIV-positive Taiwanese patients within 4 weeks of initiation of nNRTI-containing regimens.
- Published
- 2017
- Full Text
- View/download PDF
36. Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis.
- Author
-
Wang ML and Tang H
- Subjects
- Animals, Carcinoma, Hepatocellular pathology, Drug Resistance, Viral genetics, Genotype, Hepatitis B virus genetics, Hepatitis B virus pathogenicity, Hepatitis B, Chronic complications, Hepatitis B, Chronic diagnosis, Hepatitis B, Chronic virology, Humans, Liver Neoplasms pathology, Risk Factors, Antiviral Agents adverse effects, Carcinoma, Hepatocellular virology, Cell Transformation, Viral genetics, Hepatitis B Surface Antigens genetics, Hepatitis B virus drug effects, Hepatitis B, Chronic drug therapy, Liver Neoplasms virology, Mutation, Nucleosides adverse effects, Nucleotides adverse effects
- Abstract
Background: The long-term use of nucleos(t)ide analogues causes drug resistance and mutations in the HBV reverse transcriptase (RT) region of the polymerase gene. The RT region overlaps the HBV surface gene (S gene) and therefore, the mutations in the RT region simultaneously modify S gene sequence. Certain mutations in the RT region bring about truncated S proteins because the corresponding changed S gene encodes a stop codon which results in the loss of a large portion of the C-terminal hydrophobic region of HBV surface protein. The rtA181T/sW172*, rtM204I/sW196* and rtV191I/sW182* are the most frequently reported drug-resistant mutations with C-terminal truncation, these mutations have oncogenic potential., Data Sources: PubMed and Web of Science were searched using terms: "hepatitis B virus", "HBV drug resistance mutation", "HBV surface protein", "HBV truncation", "hepatocellular carcinoma", "rtA181T/sW172*", "rtM204I/sW196*", "rtV191I/sW182*", and relevant articles published in English in the past decades were reviewed., Results: The rtA181T/sW172* and rtV191I/sW182* mutants occurred more frequently than the rtM204I/sW196* mutant both in chronic hepatitis B patients and the HBV-related hepatocellular carcinoma tissues. Although these mutations occur naturally, nucleos(t)ide analogues therapy is the main driving force. These mutations may exist alone or coexist with other HBV mutations. All these three mutants impair the virion secretion and result in HBV surface protein retention and serum HBV DNA level reduction. These mutations possess potential carcinogenic properties. The three mutations are resistant to more than one nucleos(t)ide analogue and therefore, it is difficult to treat the patients with the truncated mutations., Conclusions: Nucleos(t)ide analogues induce drug resistance and HBV S gene truncated mutations. These mutations have potential carcinogenesis.
- Published
- 2016
- Full Text
- View/download PDF
37. Effects of nucleos(t)ide analogs on body composition in HBV-infected men: An age- and BMI-matched, cross-sectional study.
- Author
-
Yao J, Zhou L, Hua X, Kong M, Chen Y, and Duan Z
- Subjects
- Adipose Tissue drug effects, Adipose Tissue metabolism, Adipose Tissue pathology, Adult, Body Mass Index, Case-Control Studies, Cross-Sectional Studies, Hepatitis B, Chronic metabolism, Humans, Lipid Metabolism drug effects, Male, Middle Aged, Nucleosides adverse effects, Nucleotides adverse effects, Antiviral Agents adverse effects, Body Composition drug effects, Hepatitis B, Chronic drug therapy, Hepatitis B, Chronic pathology
- Abstract
Objective: Chronic hepatitis B (CHB) requires long-term treatment with nucleos(t)ide analogs (NAs). The goal of the present study was to evaluate the effects of long-term treatment with NAs on body composition in men with CHB., Method: We performed a cross-sectional study of men infected with hepatitis B virus (HBV) who have never been on NAs with high HBV-DNA (naïve group; n = 30), those on NAs for 7 y with virologic suppression (NA-treated group; n = 50), and healthy men (control group; n = 30) matched by age and body mass index (BMI) to evaluate whether body composition differed. Body composition was assessed by multiple-frequency bioelectrical impedance analysis. All patients and healthy controls underwent anthropometric measures, dietary intake, and physical activity level survey., Results: Body fat mass (BFM) and visceral fat area (VFA) were significantly lower in HBV-infected men naïve to NAs than in controls (P < 0.05). With virology suppression after treatment with NAs, BFM, VFA, and waist-to-hip ratio (WHR) were significantly increased in the NA-treated group compared with the naïve group (P < 0.05). Although there were no significant differences in BFM, VFA, and WHR between NA-treated men and controls (P > 0.05), WHR in the NA-treated group was 0.94 ± 0.06, indicating central obesity. Liver function, liver stiffness measurement, dietary intake, and physical activity level were the same between NA-treated and naïve men with CHB., Conclusions: BFM and VFA is elevated in CHB men on NAs with virologic suppression compared with age and BMI-matched NA-naïve CHB men, which suggests that NAs may increase BFM and VFA of CHB men by virologic suppression. Further study is needed to clarify the adverse effects related to metabolic complications of lipid metabolism due to NA therapy., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
38. Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study.
- Author
-
Rodríguez-Nóvoa S, García-Samaniego J, Prieto M, Calleja JL, Pascasio JM, Delgado Blanco M, Crespo J, Buti M, Bonet Vidal ML, Arenas Ruiz Tapiador J, Fernández-Rodríguez C, Solá R, Fraga E, González Diéguez L, Núñez O, Praga M, Del Pino-Montes J, Romero-Gómez M, Morillas R, Diago M, and Castro Á
- Subjects
- Adolescent, Adult, Aged, Antiviral Agents administration & dosage, Creatinine urine, Cross-Sectional Studies, Disease Progression, Female, Glomerular Filtration Rate, Guanine adverse effects, Guanine analogs & derivatives, Guanine therapeutic use, Hepatitis B, Chronic urine, Humans, Male, Middle Aged, Nucleosides adverse effects, Nucleosides therapeutic use, Nucleotides adverse effects, Nucleotides therapeutic use, Retinol-Binding Proteins urine, Retrospective Studies, Spain, Tenofovir adverse effects, Young Adult, Antiviral Agents therapeutic use, Hepatitis B, Chronic drug therapy, Kidney Tubules, Proximal physiopathology, Tenofovir therapeutic use
- Abstract
Background: Cases of renal tubular dysfunction have been reported in patients with hepatitis B and in patients with human immunodeficiency virus who are undergoing tenofovir treatment. However, little is known about the impact on tubular function in patients with chronic hepatitis B (CHB) under long-term use of entecavir (ETV) and tenofovir disoproxil fumarate (TDF). We evaluated markers of renal tubular function and bone turnover in patients with CHB treated with ETV or TDF., Patients and Methods: A multicenter, cross-sectional study was performed on markers of renal tubular function and bone turnover in hepatitis B virus-monoinfected patients on long-term treatment with Entecavir or Tenofovir (the MENTE study). The analyzed parameters were: retinol-binding protein/creatinine, neutrophil gelatinase-associated lipocalin/creatinine, excretion of phosphates, uric acid excretion, glomerular filtrate, protein/creatinine, albumin/creatinine, serum creatinine, phosphate, CTX, P1NP, vitamin D, and parathormone., Results: A total of 280 patients (ETV: 89, TDF: 69, control: 122) were included in this study. The TDF group was associated with altered levels of retinol-binding protein (RBP)/creatinine (TDF 25% vs. 7% ETV and control; P<0.001). Protein/creatinine, uric acid excretion, P1NP1, and parathormone were higher in the TDF group. The proportion of patients with serum phosphate <2.5 mg/dL was higher in both the ETV and the TDF groups compared with the control. The multivariate analysis showed that the use of TDF was independently associated with a higher risk of altered excretion of RBP/creatinine (4.4; interquartile range: 1.4 to 14; P=0.013)., Conclusions: We found an independent association between TDF use and altered RBP excretion. This finding indicates subclinical tubular damage. Because tubular dysfunction can precede the decline of renal function, close monitoring of RBP levels in patients with CHB on nucleos(t)ide analog treatment must be performed for early detection of TDF-related renal toxicity. In this study, these differences in tubular function were not associated with concomitant changes in markers of bone turnover.
- Published
- 2016
- Full Text
- View/download PDF
39. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
- Author
-
Slama L, Landman R, Assoumou L, Benalycherif A, Samri A, Joly V, Pialoux G, Valin N, Cabié A, Duvivier C, Lambert-Niclot S, Marcelin AG, Peytavin G, Costagliola D, and Girard PM
- Subjects
- Adult, Africa, Aged, Anti-Retroviral Agents adverse effects, Antiretroviral Therapy, Highly Active adverse effects, Atazanavir Sulfate adverse effects, CD4 Lymphocyte Count, Darunavir adverse effects, Drug-Related Side Effects and Adverse Reactions epidemiology, Drug-Related Side Effects and Adverse Reactions pathology, Female, HIV-1 drug effects, HIV-1 isolation & purification, Humans, Male, Middle Aged, Nucleosides adverse effects, Ritonavir adverse effects, Treatment Outcome, Viral Load, Anti-Retroviral Agents therapeutic use, Antiretroviral Therapy, Highly Active methods, Atazanavir Sulfate therapeutic use, Darunavir therapeutic use, HIV Infections drug therapy, Nucleosides therapeutic use, Ritonavir therapeutic use
- Abstract
Objectives: Boosted PIs are commonly prescribed in patients presenting with advanced HIV infection. We assessed the efficacy and tolerability of once-daily ritonavir-boosted atazanavir or darunavir plus two NRTIs in HIV-1-infected ART-naive patients with severe immunosuppression, targeting at least an 85% success rate at week 48., Methods: This 48 week, open-label, non-comparative, randomized, multicentre trial included ART-naive patients with CD4 cell counts <200 cells/mm(3), with plasma HIV-1 RNA >1000 copies/mL and without genotypic mutations conferring resistance to the study drugs. Patients were randomized (1:1) to receive once-daily atazanavir/ritonavir (300/100 mg) or darunavir/ritonavir (800/100 mg) plus tenofovir disoproxil fumarate/emtricitabine or abacavir/lamivudine. The primary endpoint was treatment success, defined as plasma HIV-1 RNA ≤50 copies/mL at week 48 and no permanent PI/ritonavir discontinuation. The study was registered with ClinicalTrials.gov (NCT01928407)., Results: One hundred and twenty patients were enrolled: 77% were men, 30% were born in Africa and 39% had AIDS. The median baseline CD4 and plasma HIV-RNA values were 69 cells/mm(3) and 5.4 log10 copies/mL. All but four patients received tenofovir disoproxil fumarate/emtricitabine. The week 48 treatment success rate was 66% (95% CI 54%-78%) with atazanavir/ritonavir and 80% (95% CI 68%-89%) with darunavir/ritonavir. The median CD4 cell count increased similarly in the two groups (Δweek 48 to week 0: +194 cells/mm(3)). Adverse events occurred in 23 and 18 patients, respectively., Conclusions: Despite good adherence, neither study regimen reached the predefined objective, suggesting a need for more potent regimens for patients with advanced HIV infection., (© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
40. Nucleoside analogs: ready to enter the era of precision medicine?
- Author
-
Ciccolini J, Serdjebi C, Le Thi Thu H, Lacarelle B, Milano G, and Fanciullino R
- Subjects
- Adult, Animals, Antineoplastic Agents adverse effects, Antineoplastic Agents pharmacokinetics, Biomarkers, Tumor metabolism, Child, Genomics methods, Humans, Neoplasms pathology, Nucleosides adverse effects, Nucleosides pharmacokinetics, Nucleosides therapeutic use, Pharmacogenetics methods, Antineoplastic Agents therapeutic use, Neoplasms drug therapy, Precision Medicine methods
- Abstract
Introduction: The term 'precision medicine' has garnered significant attention in the oncological setting in relation to attempts to optimize anticancer treatment. Precision medicine is mostly associated with oral targeted therapies and biotherapies, however, to date classic cytotoxics still remain the backbone of most regimens for treating solid tumors or in hematology, both in children and in adults. Among the existing cytotoxic therapies, nucleosides are widely used for treating a variety of cancerous diseases, alone or as part of combination therapies., Areas Covered: Several markers at the tumor or the germinal levels have been identified as being associated with clinical outcome (e.g. CDA, DPD, EONFS1, hENT1, TYMS, MTHFR), however little effort has been made to implement bioguided therapy with nucleoside analogs. Still, growing clinical evidence has demonstrated how the efficacy-toxicity balance of these drugs could be improved by developing bioguided strategies at the bedside. This review covers the current knowledge regarding putative markers to be used with nucleoside analogs, what is known on their pharmacokinetic/pharmacodynamic relationships, and provides clues for implementing precision medicine with those old, yet pivotal drugs., Expert Opinion: Through a variety of strategies ranging from pharmacogenetics, tumor genomics and pharmacokinetically-driven adaptive dosing procedures, nucleoside analogs could enter the era of precision medicine in oncology.
- Published
- 2016
- Full Text
- View/download PDF
41. Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation.
- Author
-
Lee TY, Lin JT, Zeng YS, Chen YJ, Wu MS, and Wu CY
- Subjects
- Aged, Carcinoma, Hepatocellular etiology, Cohort Studies, Female, Hepatitis B drug therapy, Humans, Liver Neoplasms etiology, Male, Middle Aged, Nucleosides adverse effects, Prognosis, Proportional Hazards Models, Antiviral Agents adverse effects, Carcinoma, Hepatocellular surgery, Catheter Ablation, Hepatitis B complications, Liver Neoplasms surgery, Neoplasm Recurrence, Local epidemiology
- Abstract
Unlabelled: Radiofrequency ablation (RFA) is the best choice for curative treatment of hepatocellular carcinoma (HCC) cases not suitable for surgical intervention, but efforts should be made to reduce the risk of tumor recurrence. We aimed to investigate the association between nucleos(t)ide analog (NA) therapy for hepatitis B virus (HBV) and the risk of HCC recurrence post-RFA. Using the Taiwan National Health Insurance Research Database between July 1, 2004 and December 31, 2012, we screened 48,807 patients with newly diagnosed HBV-related HCC. We identified 850 patients (200 patients who used NAs for more than 90 days and 650 who never used NA post-RFA) who received RFA as a potentially curative treatment for HCC. Patients in the NA-treated cohort were randomly matched 1:2 with patients in the untreated cohort by age, sex, cirrhosis, and the time period between RFA and initiation of NA therapy. Finally, 133 patients were recruited in the NA-treated group and 266 in the untreated group for analysis. Cumulative incidences of and hazard ratios (HRs) for HCC recurrence were analyzed after adjusting for competing mortality. The HCC recurrence rate of the NA-treated group was significantly lower than that of the untreated group (2-year recurrence rate: 41.8%; 95% confidence interval [CI]: 32.9-50.6 vs. 54.3%; 95% CI: 48.0-60.6; modified log-rank test: P < 0.05). In modified Cox's regression analysis, NA therapy was independently associated with a decreased risk of HCC recurrence (HR, 0.69; 95% CI: 0.50-0.95; P < 0.05). Multivariate stratified analyses verified the association of NA therapy and decreased HCC recurrence in almost all patient subgroups., Conclusion: NA therapy was associated with a decreased risk of HCC recurrence among patients with HBV-related HCC post-RFA., (© 2015 by the American Association for the Study of Liver Diseases.)
- Published
- 2016
- Full Text
- View/download PDF
42. [Biomarkers of renal impairment and their application in renal function monitoring during treatment with nucleos(t)ide analogues].
- Author
-
Li HS and Ma H
- Subjects
- Antiviral Agents adverse effects, Biomarkers, Glomerular Filtration Rate physiology, Hepatitis B, Chronic physiopathology, Hepatitis B, Chronic virology, Humans, Kidney physiopathology, Nucleosides adverse effects, Nucleotides adverse effects, Antiviral Agents therapeutic use, Glomerular Filtration Rate drug effects, Hepatitis B, Chronic drug therapy, Kidney drug effects, Nucleosides therapeutic use, Nucleotides therapeutic use
- Abstract
Currently, nucleos(t)ide analogues (NAs) are the major drugs for the antiviral treatment of chronic hepatitis B (CHB), including lamivudine, adefovir dipivoxil, telbivudine, entecavir, and tenofovir disoproxil. Since many patients need to take NAs orally for a long time to inhibit viral replication, the safety of long-term administration is an important factor for selecting drugs in clinical practice. In recent years, some studies have been focusing on the impact of long-term administration of NAs on glomerular filtration function and renal tubular function in such patients. At the same time, more and more biomarkers for evaluating renal impairment have been used in clinical practice, but the applicability of most biomarkers in CHB patients remains uncertain. This review describes the biomarkers that are currently used or have a potential clinical value and investigates the application of such biomarkers in CHB patients in future.
- Published
- 2016
- Full Text
- View/download PDF
43. Does Nucleos(t)ide Analogues Treatment Affect Renal Function in Chronic Hepatitis B Patients Who Have Already Decreased eGFR? A Longitudinal Study.
- Author
-
Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Chang KC, Yen YH, Lin MT, and Hu TH
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Prospective Studies, Retrospective Studies, Time Factors, Antiviral Agents administration & dosage, Antiviral Agents adverse effects, Hepatitis B, Chronic drug therapy, Hepatitis B, Chronic physiopathology, Kidney physiopathology, Nucleosides administration & dosage, Nucleosides adverse effects, Renal Insufficiency, Chronic chemically induced, Renal Insufficiency, Chronic physiopathology
- Abstract
This study aimed to assess the renal function in chronic hepatitis B (CHB) patients who received nucleos(t)ide analogues (NAs) therapy using estimated glomerular filtration rate (eGFR) titer. We performed a longitudinal observational study of 37 tenofovir-, 42 telbivudine-, and 62 entecavir-naïve CHB patients, who had impaired renal function (eGFR, 90-30 ml/min/1.73m2) without history of diabetes, hypertension, and chemotherapy. Calculation and evaluation of eGFR was performed with the Modification of Diet in Renal Disease, Chronic Kidney Disease Epidemiology Collaboration, and Cockcroft-Gault formula at pretreatment, at baseline, and after the 1st and 2nd year of treatment. The eGFR was significantly increased in patients given telbivudine or entecavir (p = 0.003 and p = 0.012, respectively), but the eGFR was decreased in patients given tenofovir (p = 0.001) after 2 years of treatment. Of all patients, eGFR was stable one year prior to treatment. If we analyzed the renal function by change of chronic kidney disease (CKD) category with a change of 25% of eGFR, the proportion of uncertain drop (drop in CKD category with <25% decrease in eGFR) and certain drop (drop in CKD category with ≧25% decrease in eGFR) in tenofovir group was smaller (5.4%) than those of telbivudine (12.9%) or entecavir (6.5%). Furthermore, telbivudine had the lowest stable rate (76.2%), the highest certain rise rate (9.5%), and certain drop rate (7.1%) compared to the other groups (p = 0.049). In conclusion, in NAs-naïve CHB patients with impaired renal function, telbivudine and entecavir resulted in a significant increase in eGFR while tenofovir resulted in a significant decrease after a 2-year treatment. Interestingly, TDF had the lowest proportion of patients reclassified to certain and uncertain drop groups; in contrast, LdT had a higher proportion in both raise and drop groups. The outcomes of this renal effect remain to be determined.
- Published
- 2016
- Full Text
- View/download PDF
44. Intracellular Metabolism of Nucleoside/Nucleotide Analogues: a Bottleneck to Reach Active Drugs on HIV Reverse Transcriptase.
- Author
-
Varga A, Lionne C, and Roy B
- Subjects
- Anti-HIV Agents adverse effects, Humans, Molecular Structure, Nucleosides adverse effects, Nucleosides chemistry, Nucleotides adverse effects, Nucleotides chemistry, Phosphorylation, Reverse Transcriptase Inhibitors adverse effects, Anti-HIV Agents pharmacology, HIV Reverse Transcriptase metabolism, Nucleosides pharmacology, Nucleotides pharmacology, Reverse Transcriptase Inhibitors pharmacology
- Abstract
Background: To date, the most effective way to treat HIV is to use a highly active antiretroviral therapy (HAART) that combines three or more different drugs. The usual regimen consists of two nucleoside reverse transcriptase inhibitors and either a protease inhibitor, a non-nucleoside reverse transcriptase inhibitor, or an integrase strand transfer inhibitor. Due to the emerging resistance against the nucleoside analogues in use, there is a continuous need for the development of such therapeutic molecules with different structural features., Objectives: In this review, we would like to summarize the state of knowledge of the antiretroviral nucleoside analogues intracellular metabolism. Indeed, these molecules have to be phosphorylated in the cell, a process that is often a bottleneck, to produce their pharmacologically active triphosphorylated forms. These forms can be used by the HIV reverse transcriptase. Because they lack a 3'-hydroxyl group, they block further extension of the viral DNA, and finally lead to early chain termination. Several kinases can act on the phosphorylation of these drugs; most of them have low nucleoside/nucleotide specificity. On the other hand, there are also nucleotidases in the cell, which can reverse the phosphorylation process, thus shifting the equilibrium from the active triphosphorylated state to the non-active (not-, mono- or di-phosphorylated) states of these analogues., Conclusion: Here, we would like to bring to the attention of the medicinal chemists that they have to take into account the limitation of the intracellular phosphorylation machinery when designing new nucleoside analogue drugs.
- Published
- 2016
- Full Text
- View/download PDF
45. Naringin Ameliorates HIV-1 Nucleoside Reverse Transcriptase Inhibitors- Induced Mitochondrial Toxicity.
- Author
-
Oluwafeyisetan A, Olubunmi A, and Peter O
- Subjects
- Administration, Oral, Animals, Anti-HIV Agents administration & dosage, Liver drug effects, Liver pathology, Male, Nucleosides administration & dosage, Rats, Wistar, Reverse Transcriptase Inhibitors administration & dosage, Treatment Outcome, Anti-HIV Agents adverse effects, Drug-Related Side Effects and Adverse Reactions prevention & control, Flavanones administration & dosage, Free Radical Scavengers administration & dosage, Mitochondria drug effects, Nucleosides adverse effects, Reverse Transcriptase Inhibitors adverse effects
- Abstract
Background: Mitochondrial reactive oxygen species (ROS) generation and defective oxidative phosphorylation (OXPHOS) have been proposed as possible mechanisms underlying the development of nucleoside reverse transcriptase inhibitors (NRTIs)-induced mitochondrial toxicities. Available options in managing these complications have, so far, produced controversial results, thus necessitating further research into newer agents with promise. Antioxidant and free-radical scavenging effects of naringin, a plant-derived flavonoid, have previously been demonstrated., Objective: This study was designed to investigate the effects of naringin on NRTIs-induced mitochondrial toxicity., Methods: Wistar rats were randomly divided into Zidovudine (AZT)-only (100 mg/kg body weight BW); AZT+Naringin (100+50 mg/kg BW); AZT+Vitamin E (100+100 mg/kg BW); Stavudine (d4T)- only (50 mg/kg BW); d4T+Naringin (50+50 mg/kg BW); d4T+Vitamin E (50+100 mg/kg BW) and Vehicle (3.0 mL/kg BW)-treated groups, respectively. After 56 days of oral daily dosing, rats were euthanized by halothane overdose, blood collected by cardiac puncture and livers promptly excised for further biochemical and ultrastructural analyses. </p> Results: AZT- or d4T-only caused significant mitochondrial dysfunction and mitochondrial ultrastructural damage compared to controls, while either naringin or vitamin E reversed indices of mitochondrial dysfunction evidenced by significantly reduced mitochondrial malondialdehyde (MDA) and blood lactate concentrations, increased liver manganese superoxide dismutase (MnSOD) activity and upregulate expression of mitochondrial-encoded subunit of electron transport chain (ETC) complex IV protein compared to AZT- or d4T-only treated rats. Furthermore, naringin or vitamin E, respectively, ameliorated mitochondrial damage observed in AZT- or d4T-only treated rats., Conclusion: Naringin ameliorated oxidative stress and NRTI-induced mitochondrial damage and might, therefore, be beneficial in managing toxicities and complications arising from NRTI use.
- Published
- 2016
- Full Text
- View/download PDF
46. Application of nucleoside analogues to liver transplant recipients with hepatitis B.
- Author
-
Song ZL, Cui YJ, Zheng WP, Teng DH, and Zheng H
- Subjects
- Antiviral Agents adverse effects, Drug Resistance, Viral, End Stage Liver Disease diagnosis, End Stage Liver Disease virology, Hepatitis B virus growth & development, Hepatitis B, Chronic complications, Hepatitis B, Chronic diagnosis, Humans, Nucleosides adverse effects, Recurrence, Treatment Outcome, Waiting Lists, Antiviral Agents therapeutic use, End Stage Liver Disease surgery, Hepatitis B virus drug effects, Hepatitis B, Chronic drug therapy, Liver Transplantation adverse effects, Nucleosides therapeutic use, Transplant Recipients, Virus Activation drug effects
- Abstract
Hepatitis B is a common yet serious infectious disease of the liver, affecting millions of people worldwide. Liver transplantation is the only possible treatment for those who advance to end-stage liver disease. Donors positive for hepatitis B virus (HBV) core antibody (HBcAb) have previously been considered unsuitable for transplants. However, those who test negative for the more serious hepatitis B surface antigen can now be used as liver donors, thereby reducing organ shortages. Remarkable improvements have been made in the treatment against HBV, most notably with the development of nucleoside analogues (NAs), which markedly lessen cirrhosis and reduce post-transplantation HBV recurrence. However, HBV recurrence still occurs in many patients following liver transplantation due to the development of drug resistance and poor compliance with therapy. Optimized prophylactic treatment with appropriate NA usage is crucial prior to liver transplantation, and undetectable HBV DNA at the time of transplantation should be achieved. NA-based and hepatitis B immune globulin-based treatment regimens can differ between patients depending on the patients' condition, virus status, and presence of drug resistance. This review focuses on the current progress in applying NAs during the perioperative period of liver transplantation and the prophylactic strategies using NAs to prevent de novo HBV infection in recipients of HBcAb-positive liver grafts.
- Published
- 2015
- Full Text
- View/download PDF
47. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects.
- Author
-
Wong GL, Tse YK, Wong VW, Yip TC, Tsoi KK, and Chan HL
- Subjects
- Acute Kidney Injury chemically induced, Acute Kidney Injury epidemiology, Administration, Oral, Adult, Antiviral Agents administration & dosage, Antiviral Agents adverse effects, Cohort Studies, Databases, Factual, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Fractures, Bone chemically induced, Fractures, Bone epidemiology, Hepatitis B, Chronic mortality, Hong Kong, Humans, Male, Middle Aged, Nucleosides adverse effects, Nucleotides adverse effects, Retrospective Studies, Risk Assessment, Severity of Illness Index, Time Factors, Treatment Outcome, Hepatitis B, Chronic diagnosis, Hepatitis B, Chronic drug therapy, Nucleosides administration & dosage, Nucleotides administration & dosage
- Abstract
Unlabelled: Widespread and long-term use of oral nucleos(t)ide analogs (NAs) to treat chronic hepatitis B (CHB) brings about safety data in a real-life setting. We aimed to determine the risks of renal and bone side effects in patients receiving or who have received NAs as CHB treatment. A territory-wide cohort study using the database from Hospital Authority, the major provider of medical services in Hong Kong, was conducted. We identified CHB patients by International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes, diagnosed between 2000 and 2012. The primary events were renal (incident renal failure and renal replacement therapy [RRT]) and bone events (incident hip, vertebral, and all fractures). A 3-year landmark analysis was used to evaluate the relative risk of primary outcome in patients with or without NA treatment. A total of 53,500 CHB patients (46,454 untreated and 7,046 treated), who were event free for 3 years, were included in the analysis. At a median follow-up of 4.9 years, chronic renal failure, RRT, all fractures, hip fractures, and vertebral fractures occurred in 0.6%, 0.2%, 0.7%, 0.1%, and 0.1% of untreated subjects and 1.4%, 0.7%, 1.3%, 0.2%, and 0.2% of treated subjects. After propensity score weighting, NA therapy did not increase the risk of any of the events (hazard ratios [HRs] ranged from 0.79 to 1.31; P = 0.225-0.887). Exposure to nucleotide analogues, compared with nucleoside analogs, increased the risk of hip fracture (HR = 5.69; 95% confidence interval: 1.98-16.39; P = 0.001), but not other events (HR = 0.58-1.44; P = 0.202-0.823)., Conclusions: NA treatment does not increase the risk of renal and bone events in general. Nucleotide analogs may increase the risk of hip fracture, but the overall event rate is low., (© 2015 by the American Association for the Study of Liver Diseases.)
- Published
- 2015
- Full Text
- View/download PDF
48. Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs.
- Author
-
Serdjebi C, Milano G, and Ciccolini J
- Subjects
- Adult, Animals, Antimetabolites, Antineoplastic adverse effects, Antimetabolites, Antineoplastic pharmacology, Child, Cytidine Deaminase genetics, Genotype, Humans, Nucleosides adverse effects, Nucleosides pharmacokinetics, Nucleosides pharmacology, Polymorphism, Genetic, Antimetabolites, Antineoplastic pharmacokinetics, Cytidine Deaminase metabolism, Neoplasms drug therapy
- Abstract
Introduction: Nucleosidic analogs such as pyrimidine and purine derivatives are mainstay in the field of treating cancers, both in adults and in children. All these drugs act as antimetabolite compounds, that is, they interfere with the ability of cancer cells to synthesize the nucleosides or the nucleotides necessary for proliferation and progression. As with most cytotoxics, maintaining patients in their therapeutic window is challenging, and predicting changes in drug exposure is critical to ensure an optimal efficacy/toxicity balance., Areas Covered: Among the antimetabolites, a small but widely prescribed number of drugs (i.e., gemcitabine, capecitabine, cytarabine, azacytidine) share a same metabolic pattern driven by a liver enzyme, cytidine deaminase (CDA), coded by a gene displaying several genetic and epigenetic polymorphisms. Consequently, CDA activity is erratic, ranging from deficient to ultra-rapid deaminator patients, with subsequent impact on drug pharmacokinetics and pharmacodynamics eventually. This review provides an update on the variety of clinical studies and case-reports investigating on CDA status as a marker for clinical outcome in cancer patients treated with nucleosidic analogs., Expert Opinion: Whereas sorting patients on the basis of their CDA genotype remains tricky because of unclear genotype-to-phenotype relationships, developing functional strategies (i.e., phenotype-based status determination) could help to use CDA status as a biomarker for developing adaptive dosing strategies with nucleosidic analogs.
- Published
- 2015
- Full Text
- View/download PDF
49. Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B.
- Author
-
Qi X, Wang J, Chen L, Huang Y, Qin Y, Mao R, and Zhang J
- Subjects
- Adenine analogs & derivatives, Adenine therapeutic use, Adult, Aged, Antiviral Agents administration & dosage, Antiviral Agents adverse effects, Drug Therapy, Combination, Female, Glomerular Filtration Rate, Guanine analogs & derivatives, Guanine therapeutic use, Humans, Lamivudine therapeutic use, Male, Middle Aged, Nucleosides administration & dosage, Nucleosides adverse effects, Nucleotides administration & dosage, Nucleotides adverse effects, Organophosphonates therapeutic use, Retrospective Studies, Telbivudine, Thymidine analogs & derivatives, Thymidine therapeutic use, Antiviral Agents therapeutic use, Hepatitis B, Chronic drug therapy, Nucleosides therapeutic use, Nucleotides therapeutic use
- Abstract
Monotherapy with telbivudine or adefovir can affect estimated the glomerular filtration rate (eGFR). However, only a few studies have assessed changes in eGFR in patients who have chronic hepatitis B (CHB) and are receiving nucleos(t)ide analogue (NA) combination therapy. In our study, we aimed to evaluate the effects of long-term NA combination therapy on eGFR in Chinese CHB patients. This retrospective study included 195 CHB patients. Patient subgroups included those treated with lamivudine plus adefovir (n = 73), telbivudine plus adefovir (n = 51), and entecavir plus adefovir (n = 35); untreated patients (n = 36) served as a control group. After an average follow-up duration of 24 months with combination therapy, analysis of changes in eGFR from baseline values, calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) formulas, showed decrease by 11.08 and 18.34 mL/min (P < .001), respectively, in the lamivudine plus adefovir group; decrease by 3.73 and 10.04 mL/min (P = .012), respectively, in the entecavir plus adefovir group; and increase by 0.91 and 2.12 mL/min (P = .46), respectively, in the telbivudine plus adefovir group. The eGFR in the telbivudine plus adefovir group was similar to that for the untreated group. The eGFR decreases due to adefovir therapy could be rescued by adding telbivudine, and the eGFR increase due to telbivudine could be compromised by adding adefovir. Adefovir in combination with lamivudine or entecavir therapy was significantly associated with decreased eGFR, but telbivudine could rescue the eGFR decrease that results from adefovir treatment.
- Published
- 2015
- Full Text
- View/download PDF
50. Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China.
- Author
-
Qi X, Wang JY, Mao RC, and Zhang JM
- Subjects
- Adolescent, Adult, Aged, Antiviral Agents adverse effects, China, Cohort Studies, Female, Humans, Male, Middle Aged, Nucleosides adverse effects, Nucleotides adverse effects, Prospective Studies, Young Adult, Antiviral Agents therapeutic use, Glomerular Filtration Rate drug effects, Hepatitis B, Chronic drug therapy, Nucleosides therapeutic use, Nucleotides therapeutic use
- Abstract
Chronic hepatitis B therapy with nucleos(t)ide analogues, particularly tenofovir or adefovir, may affect renal function. To date, there has not been a head-to-head controlled study to assess estimated glomerular filtration rate (eGFR) fluctuations in nucleos(t)ide-treated CHB patients. We aimed to evaluate the long-term effects of nucleos(t)ide on eGFR in Chinese patients with chronic hepatitis B. This prospective cohort study included 275 patients. Patient subgroups included those treated with lamivudine (n = 50), adefovir (n = 60), telbivudine (n = 68) and entecavir (n = 61); untreated patients (n = 36) served as control. After an average follow-up duration of 23 months, eGFR calculated by Cockcroft-Gault and Modification of Diet in Renal Disease formulas increased by 18.35 mL/min and 19.34 mL/min (P < 0.0001) in the telbivudine group, respectively, and decreased by 10.95 mL/min and 12.17 mL/min (P = 0.0001) in the adefovir group, respectively. Even if renal function was normal or mildly impaired at baseline, eGFR increased significantly more in the telbivudine group than in the other groups (P < 0.001). More patients in the adefovir group (23%) had a ≥20% decrease in eGFR than the other groups (P < 0.0001). More patients in the telbivudine group (31%) had a ≥20% increase in eGFR than the other groups (P < 0.0001). In conclusion, prolonged telbivudine therapy resulted in improved eGFR, while adefovir therapy was associated with decreased eGFR. Lamivudine and entecavir therapy did not significantly influence eGFR., (© 2014 John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.